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ABSTRACT

Chen, Tzu Ying. Ph.D., Purdue University, December 2013. Brain Bioavailability of
Polyphenols: Implications for Delivery of Brain Health Benefits. Major Professor: Elsa M.
Janle and Mario G. Ferruzzi.

Consumption of fruits and vegetables has been associated with neuroprotection and
cognitive benefits throughout the life span. These associations have sparked interest in
plant derived polyphenols as biologically active agents with potential for targeting brain
benefits. However, little is known regarding the ability of the polyphenols or their
metabolites from polyphenol rich products to cross the blood brain barrier, and be
available for biological action. Furthermore, additional insight is needed on factors
affecting the absorption and brain distribution of polyphenol metabolites in vivo. To fill
gap in current knowledge, this thesis will focus on the effects of diabetogenic diet and
diabetic state which have been considered potential risk factors for neurodegenerative
disease on polyphenol bioavailability from a ‘Standardized Grape Polyphenol’ (grape
seed extract, Concord grape juice and resveratrol). Additionally, this thesis will provide
novel evidence on plasma pharmacokinetics and regional brain distribution of
polyphenol metabolites from apple/grape seed and bilberry extracts in a weaning piglet
model.

xvi
We have found that background diabetogenic diet had limited effects on polyphenol
plasma levels and brain bioavailability in a healthy Sprague Dawley rat model. However,
the diabetic state negatively influenced polyphenol metabolite levels in plasma and
brain tissues, possibly in part, due to excessive excretion in urine. By using a young
piglet model, we determined plasma pharmacokinetics of polyphenol metabolites using
physiological and pharmacological doses of apple/grape seed and bilberry extracts. We
found that in a physiological dose achievable by supplementation, polyphenol
metabolites were able to cross blood brain barrier to deposit in the brain. There was a
difference in regional brain deposition with cerebellum being a preferred site for
accumulation. Our data warrant the future design of functional tests on aging related
diseases, specifically Alzheimer’s disease as well as improvement in cognitive and
memory in healthy infant/child model.
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CHAPTER 1.

1.1

INTRODUCTION

Introduction

Consumption of polyphenol rich foods are believed to offer health benefits for all age
groups, including neuroprotective effects, especially against neurodegenerative diseases
such as Alzheimer’s disease (AD) in the elderly and, to a lesser extent, protection of
early brain development in the young. Polyphenols rich food and supplements, in the
form of grape seed extract (Wang, Ho et al. 2008), resveratrol (Vingtdeux, Giliberto et al.
2010) and red wine (Ho, Chen et al. 2009) have specifically demonstrated the ability to
offer protection against the brain aging processes leading to Alzheimer’s disease in
rodent models. On the other hand, evidence of polyphenol benefits on the young have
been focused on various insults to the brain (Loren, Seeram et al. 2005; Candelario Jalil,
de Oliveira et al. 2007; West, Atzeva et al. 2007; Liu and Yu 2008; Narita, Hisamoto et al.
2011). Few have demonstrated hard data in support benefits to neuronal growth and
brain development in healthy models (Patel, Scott et al. 2011). However, considering
the potential for brain bioactive nature of these phytochemicals, it is not surprising that
interest in research addressing the benefits for both young and old is growing. A key
component to support such research is defining the bioactive polyphenol forms and
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their ability to penetrate the blood brain barrier and become available to brain
tissues for action. It is crucial to understand polyphenol absorption and metabolism
(bioavailability) in order to translate their physiological impacts of polyphenols into
benefits in diseased as well as the healthy young population.
Several factors are known to impact polyphenol bioavailability including food
processing (Ferruzzi 2010; Neilson and Ferruzzi 2011; Gupta, Kagliwal et al. 2013), food
matrix (Scholz and Williamson 2007; Palafox Carlos, Ayala Zavala et al. 2011; Williamson
2013) and macronutrients composition (Ortega, Reguant et al. 2009; Jaldappagari,
Balakrishnan et al. 2013). Specifically, fat content in the diet has increased dramatically
over the years which has led to a severe obesity epidemic, furthering increasing
development of metabolic syndrome and type II diabetes (NHANES 2010). The change in
the dietary pattern toward a diabetogenic diet has been associated with the increased
susceptibility to neurodegenerative disorders possibly due to the disruption of neuronal
insulin metabolism (Pasinetti, Wang et al. 2011; Accardi, Caruso et al. 2012). Since we
aim to target AD by the use of polyphenol rich extracts, an understanding of the impact
of dietary fat content on polyphenol absorption is needed for further therapeutic
studies. Furthermore, habitual consumption of diabetogenic diet creates the conditions
for the development of type II diabetes (Pasinetti, Wang et al. 2011). People with type II
diabetes have double the risk for later dementia and Alzheimer’s disease (Ott, Stolk et al.
1999; Willette, Xu et al. 2013). This relationship warrants the suitability of type II
diabetes to be the model to investigate the effect of disease state on polyphenol
bioavailability. Despite its much needed attention, the possibility that a diabetogenic
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diet and the diabetic condition might influence polyphenol bioavailability has never
been studied. In the elderly, polyphenols may be beneficial in prevention of
neurodegeneration and improving and preserving cognitive function. In the young, the
benefits may be linked to neuronal improvement. However, knowledge of polyphenols
and brain health in healthy models is lacking. To gain more insight into the absorption
and brain distribution of polyphenols from extracts in the healthy young population, we
employed a piglet model. Overall, this dissertation will discuss the studies conducted
aiming to obtain better understanding on the roles of polyphenol rich products in AD
prevention/treatment and young brain development. The data discussed merit the
possibilities for further therapeutic studies regarding these potential polyphenol rich
extracts.

1.2

Outline and Organization

Chapter 2 will discuss the properties of key bioactive polyphenol compounds present
in grapes, apples and berries, namely, flavan 3 ols, quercetin, anthocyanins and
resveratrol and their benefits in young and old populations. Additionally, a summary of
current findings of bioavailability studies and brain distribution of polyphenols as a
function of different polyphenol dosages will also be highlighted. Chapter 3, 4 and 5 will
highlight the investigation of the effects of diabetogenic diet and diabetic condition on
polyphenol bioavailability in rodent models and the regional brain bioavailability in a
young swine model with special focus on plasma pharmacokinetics and brain
distribution.
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CHAPTER 2.

2.1

LITERATURE REVIEW

Classification of Polyphenols

Polyphenols are plant secondary metabolites produced, in part, as a self defense
mechanism to protect the plants from stress and disease including pathogenic attack,
overexposure to ultraviolet radiation, and heat/drought (Davinelli, Sapere et al. 2012).
‘’Polyphenol’’ is a general term for a broad class of compounds with chemical structures
characterized by multiple aromatic/phenolic rings. Considering the broad possibilities
for substitution to a basic phenolic structure, polyphenols have been broadly divided
into two subgroups, flavonoids and non flavonoids (Figure 2.1). Common dietary
flavonoids are flavonols, flavones, isoflavones, flavanones, anthocyanidins and flavan 3
ols. Non flavonoids include phenolic acids (hydroxybenzoic acids and hydroxycinnamic
acids), lignans and stilbenes.
Flavonoids share the same C6 C3 C6 backbone with two aromatic rings A and B which
are bound together by an oxygenated heterocyclic ring C illustrated in Figure 2.1
(Manach, Scalbert et al. 2004). The number and type of substitution of the backbone
distinguishe one flavonoid from another. Polyphenol rich foods like grape seed extract,
Concord grape juice, resveratrol, bilberry and apple extracts used in the present
research projects contains unique polyphenol subclasses. They are flavan 3 ols (catechin
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and epicatechin), flavonol (quercetin), anthocyanidin glycosides and one non flavonoid
(resveratrol) which will be the main focus of this discussion with special focus on their
distinct structure and major food sources.
Flavanones – naringenin, hesperetin
Flavones – apigenin, luteolin
Isoflavones – daizein, genistein

Flavonoids

Flavn-3-ols – catechin, epicatechin

Flavonols – quercetin, kaempferol, myricetin
Anthocyanidins – malvidin, petunidin, peonidin,
delphinidin, cyanidin

Phenolic acids – hydroxybenzoic acids and hydroxycinnamic acids
Polyphenols

Hydroxybenzoic acids

Hydroxycinnamic acids

Gallic acid: R1=R2=R3=OH
Protocatechuic acid: R1=R2=OH, R3=H
Non-flavonoids

Coumaric acid: R1=OH
Caffeic acid: R1=R2=OH
Ferulic acid: R1=OCH3, R2=OH

Lignans
Secoisolariciresinol

Stilbenes – resvetatrol, piceatannol

trans stilbene

Figure 2.1. Classification of polyphenols.

cis stilbene
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2.1.1 Dietary Intake of Polyphenols
Estimation of polyphenol intake is important yet not readily accessible or likely
accurate due to the difficulties in obtaining quantitative estimates of food content and
consumption. The first report to ever document flavonoid intake, was released in 1976
and the estimation was 1g/d for U.S. adults (Kühnau 1976). Since then, average
polyhphenol consumption of 1g/d has been considered to be the standard for
polyphenol research. In 1995, the ‘Seven countries study’ was published documenting
the average flavonoid intake of people from Greece, Italy, Finland, U.S., Japan,
Netherland and former Yugoslavia (Croatia and Serbia) (Hertog, Kromhout et al. 1995).
The report initiated studies to research polyphenol intake from different countries.
However, the values reported in recent years were much lower than 1g/d estimated in
1976. The variations could be due to the methodology used such as dietary data
acquisition, analytical methods, food and phenolic databases as well as the targeted
polyphenol classes investigated. The background of each population chosen can
contribute to the variation such as age, gender and health condition.
One of the most important factors is the inclusion of the numbers of flavonoids in the
study. Most studies estimated flavonoid intake based on flavonols (kaempferol,
myricetin and quercetin) and flavones (apigenin and luteolin) and some with the
addition of flavanones (hesperetine and naringenin). The only report including all six
flavonoids was by Chun et al. in 2007 estimating the average flavonoid intake of 189.7
mg/d for U.S. adults based on USDA database (Chun, Chung et al. 2007). Another factor
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to consider is the age groups that were included in the studies. Most studies included
subjects from 30 to 84 years old, two included all ages (Hertog, Hollman et al. 1993; Arts,
Hollman et al. 2001) and two focused on elderly with age over 50 (Hertog, Feskens et al.
1994; Boker, Van der Schouw et al. 2002). Considering the possible different
physiological impacts of flavonoids on the young and old, it is necessary to estimate the
intake according to different age groups. Taken together, it is reasonable to assume that
the average flavonoids intake of 189.7g/d reported by Chun et al. can represent
flavonoid intake for U.S. adults (Chun, Chung et al. 2007).
While the physiological impacts on different age groups might be different, it is
equally important to estimate flavonoid intake on the young and infants. There are
limited data specific to young. None of these studies estimated total flavonoid intake of
the young, but only focused on a specific flavonoid subgroup such as on
proanthocyanidins (Gu, Kelm et al. 2004) or on anthocyanins (Drossard, Alexy et al.
2011). A summary of four current available data on polyphenol intake of infants and
toddlers is shown in Table 2.1. The data on total flavonoid intake of the young including
infants and children is much needed to connect the intake to physiological intakes for
young age group.
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Table 2.1. Polyphenol intake of infants and children.
Flavonoid Class
Anthocyanins

Flavan 3 ols
(monomer)

Flavonols

Flavonoid
Database
USDA 2007
(Release 2)

Mean Intake
(mg per day)
0.05
1.51
5.27
6.24
6.99
8.11
8.69

Australia

USDA 2003
(Release 1)

2 3y
4 7y
8 11 y

Australia

USDA 2003
(Release 1)

4 6m
6 10 m
2 5y
6 11 y

USA

Calculated

2 3y
4 7y
8 11 y

Australia

USDA 2003
(Release 1)

0.0
0.71
0.59
16.25
18.45
29.36
0.2
2.3
3.9
4.4
3.11
3.63
4.19

Age
3 mo
6 mo
9 mo
12 mo
18 mo
24 mo
36 mo

Country
Germany

2 3y
4 7y
8 11 y

Primary form
Total

Reference
Drossard et al.
(2011)

Cyanidin

Johannot &
Somerset (2006)

Catechins

Johannot &
Somerset (2006)

Monomers

Gu et al. (2004)

Quercetin
Kaempferol

Johannot &
Somerset (2006)

Adopted from Ferruzzi 2010.

2.1.2 Flavan 3 ols
Structure Flavan 3 ols, also referred to as catechins, is one of the main subclasses of
flavonoids. They have the backbone structure of diphenylpropane (C6 C3 C6) which
contain a 3 carbon ring in the middle and two benzene rings with two hydroxyl groups
on both sides of the C3 ring (Song and Chun 2008) (Figure 2.2). The major flavan 3 ols
includes ( ) epicatechin (EC), ( ) epicatechin 3 gallate (ECG), ( ) epigallocatechin (EGC)
and ( ) epigallocatechin 3 gallate (EGCG) with structures shown in Figure 2.2. The
backbone structure contains two chiral carbons which generates two diastereoisomers
namely catechin and epicatechin derivatives which are monomeric units of the flavan 3
ol structure. The single unit (monomer) makes the building block for polymers called
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complex proanthocyanidins. Monomers, catechins and epicatechins, abundant in grape
seed extract will be the focus in this discussion.
OH

O

HO

OH

O
OH

OH
O

OH
OH

(+)-Catechin

(-)-epigallocatechin (EGC)

(-)-Epiatechin

(-)-epicatechin-3-gallate (ECG)

(-)-epigallocatechin-3-gallate (EGCG)

Figure 2.2. Structures of flavan 3 ols.

Food source Flavan 3 ols present in plants and foods in their free forms (EC) or as gallic
acid esters to form ECG, EGC and EGCG. According to the USDA data on 225 foods
(USDA 2003), dark chocolate contains the most catechin and epicatechin. Apple with
skin contains 0.95mg of catechin per 100g dry weight and 8.14mg of epicatechin per
100g dry weight. Another reference indicates that the number one source of flavan 3
ols is tea, second is wine, third is apple (Song and Chun 2008). There are many studies
which determined catechin amounts in different sources of foods from different origins.
For example, Pascual Teresa et al. evaluated different Spanish foodstuffs including three
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apple cultivars in which Red Delicious apples contained the highest amount of 1.57mg of
catechin/100g fresh weight and 6.37mg epicatechin/100g fresh weight (de Pascual
Teresa, Santos Buelga et al. 2000). Red grape contained 0.82mg of catechin/100g fresh
weight and 0.7mg of epicatechin/100g fresh weight (de Pascual Teresa, Santos Buelga
et al. 2000). Arts et al. measured flavan 3 ol contents in different red wines, white wines
and other beverages. They showed that Bordeaux (Appellation Controlee, Rineau, 1997)
contained the highest amount of catechin (53.4mg/L) and epicatechin (42.1mg/L) (Arts,
2000) in the red wine category. Bordeaux Sauvignon (Appellation Controlee,
Euroshopper, table wine) ranked number one in the white wine category with 4.8mg of
catechin/L and 1.2mg of epicatechin/L (Arts, van De Putte et al. 2000). A summary of
catechin and epicatechin contents derived from USDA data is shown in Table 2.2.
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Table 2.2. Summary of catechin and epicatechin contents in selected foods.
Content
(mg/100g)
Food Source
chocolate bar, dark
chocolate bar, milk

(+)-Catechin
11.99
2.9

(-)-Epicatechin
41.5
10.45

Apple, with skin
Apple, no skin

0.95
0.86

8.14
6.23

Grape juice, canned or bottled

0.19

0

Grape, red
Grape, black

NA
8.94

1.95
8.64

Bilberry, raw

NA

NA

Onion, cooked
Onoin, raw

NA
NA

NA
NA

Tea, black, brewed
Tea, green, brewed

1.52
2.73

2.33
8.47

Wine, red

7.61

4.29

USDA data was generated by surveying the scientific literature on 225 foods with
flavonoid contents. Data generated only by HPLC can be accepted in the USDA flavonoid
database (USDA 2003).

2.1.3 Flavonols (Quercetin)
Structure The most common flavonols are myricetin, quercetin and kaempferol,
structures are shown in Figure 2.3. The main flavonol investigated in this dissertation
was quercetin due to its abundance in Concord grape juice, wine and the apple extract
utilized in the current research (to be discussed later). Quercetin, like flavan 3 ols,
consists of two phenolic rings linked by a heterocyclic pyran ring in the middle (Harwood,
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Danielewska Nikiel et al. 2007). Generally, flavonols exist in plants in conjugated forms
with sugar moiety attached to the 3 position of the unsaturated C ring forming O
glycosides like quercetrin or rutin shown in Figure 2.3 (Harwood, Danielewska Nikiel et
al. 2007). The glycosylated flavonols are therefore the most common structure seen in
plants, not the aglycone or free flavonoid backbone structure (Murota and Terao 2003).

Flavonols

R1

R2

R3

R4

-OH

-H

-H

-H

-H

-H

-H

-H

-OH

-OH

-H

-H

Rutin

-OH

-H

-OH

Rutinose

Quercetrin

-OH

-H

OH

Rhamnose

Quercetin
Kaempferol
Myricetin
Derivatives

Figure 2.3. Structures of major flavonols and sugar derivatives.

Food source Quercetin is widely distributed in the human diet in various foods and has
been shown to be one of the most prevalent flavonoids consumed (Hertog, Hollman et
al. 1993; Hertog, Feskens et al. 1994; Knekt, Jarvinen et al. 1996; Rimm, Katan et al.
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1996; Arai, Watanabe et al. 2000). Like other flavonoids, quercetin content in plants
varies greatly due to climate, cultivar, disease pressure, post harvest handling and
processing, food preparation and also storage conditions. Key dietary sources of
quercetin include onion (347mg/kg), apple (36mg/kg), black tea (20mg/kg) (Hertog,
Hollman et al. 1993). Quercetin in Spanish cherry tomatoes was found to be 55mg/kg, in
Lollo Rosso lettuce 911mg/kg and in yellow onions 1359mg/kg (Crozier, Burns et al.
2000). A more extensive list of quercetin content in foods determined by HPLC was
composed by USDA (USDA 2003) and revised for a representative summary in Table 2.3.
The summary table depicts most relevant food sources used in our research studies
including apple, grape and bilberry products and grape juice. Onions, tea and wine are
the most commonly consumed quercetin rich products to provide a reference for
comparison.
Accumulation of quercetin derivatives by specific portions of plant tissues has been
studied. For example, a study compared flavonoid content in the flesh and in the peel of
an apple and confirmed that peel had higher levels of quercetin than the flesh (USDA
2003; Lamperi, Chiuminatto et al. 2008). Crozier et al. compared tomatoes, lettuce,
onions and peas from different varieties and found an obvious variation in quercetin
concentration in different cultivars (Crozier, Burns et al. 2000). Nemeth et al.
summarized in a review that different research groups yielded different results on
quercetin derivative contents on the same variety of onion (Nemeth and Piskula 2007).
Overall, based on the USDA data from 225 foods, food sources with most abundant
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quercetin content except for dry tea leaves are canned capers (180mg/100g), fresh dill
weed (55mg/100g) and yellow wax hot peppers (50mg/100g) (USDA 2003).
Table 2.3. Summary of quercetin content in selected foods.
Food Source
Capers, canned

Quercetin aglycon content
(mg/100g)
180.77

Apple, with skin
Apple, no skin

4.42
1.5

Grape juice, canned or bottled
Grape, red
Grape, black

0.41
3.54
2.54

Bilberry, raw

3.04

Onion, cooked
Onoin, raw

19.36
13.27

Tea, black, brewed
Tea, green, brewed

2.07
2.69

Wine, red

0.84

USDA data was generated by surveying the scientific literature on 225 foods with
flavonoid contents. Data generated only by HPLC can be accepted in the USDA flavonoid
database (USDA 2003).

2.1.4 Anthocyanidins
Structure – The five common anthocyanidin structures are shown in Figure 2.4. In
aquesous solution, a positive charge on the heterocyclic oxygen ring is responsible for
the red to blue color shown under acidic pH. Structures of anthocyanidins change
depending on environmental pH, enzymatic reactions, light, temperature and exposure
to oxygen (Yang, Koo et al. 2011). Anthocyanidins rarely exist in nature due to poor
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stability and are stabilized by glycosylation into glucosides (anthocyanins) or other
glycosylated forms (Wallace 2011). There has been over 635 anthocyanins identified
with six major glycosylated anthocyanidins including cyanidin, delphinidin, malvidin,
pelargonidin, peonidin and petunidin which account for over 90% occurring in nature
(Wallace 2011). Anthocyanins occur more frequently as 3 glucosides, 3 diglucosides and
sometimes 3 triglucosides, 3,5 diglycosides and 3,7 diglycosides. They are also found to
be glycosylated with sugars like galactose, rhamnose, arabinose and xylose (McGhie and
Walton 2007).

Anthocyanidins

R1

R2

Cyanidin (Cy)

-OH

-H

Malvidin (Mv)

-OCH3

-OCH3

-OH

-OH

Peonidin (Pn)

-OCH3

-H

Petunidin (Pt)

-OCH3

-OH

Delphinidin (Dp)

Figure 2.4. Structures of major anthocyanidins.
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Food source Anthocyanins are largely present in berries which are extensively
incorporated in the diet. The mean intake of anthocyanins in Finland has been
estimated to be 82mg/d with the main sources being berries, red wine and juice
(Manach, Williamson et al. 2005). Table 2.4. provides a representative summary of the
major anthocyanin contents in common foodstuffs analyzed by a standardized HPLC
method (USDA 2003).
Table 2.4. Summary of major anthocyanin content in selected foods.
Food Source
Grape juice, canned or
bottled
Grape, red
Grape, black
Bilberry, raw
Wine, red

Content (mg/100g)
Dp
Mv

Cy

Pn

Pt

NA
NA
NA
15.02

29.54

49.21

7.05

11.73

0.27

0.68

5.68

1.17

1.39

1

USDA data was generated by surveying the scientific literature on 225 foods with
flavonoid contents. Data generated only by HPLC can be accepted in the USDA flavonoid
database (USDA 2003).
2
Abbreviations: cyanidin (Cy), delphinidin (Dp), malvidin (Mv), peonidin (Pn) and
petunidin (Pt). Not available (NA).

2.1.5 Resveratrol
Structure Resveratrol (3, 5, 4’ – trihydroxystilbene) is a phenolic compound in the
stilbene family. Resveratrol exists in two structural isomeric forms, cis and trans (Figure
2.5.) with trans form being more common in food stuffs and possessing greater
bioactivity (Wenzel and Somoza 2005). Resveratrol was first discovered in high
abundance by Japanese scientists in the early 1980 in the roots of Polygonum

17
cuspidatum (Arichi, Kimura et al. 1982). Resveratrol was later hypothesized to be the
component of red wine responsible for the French Paradox, which is the lower risk of
coronary heart disease in France, despite their diet high in saturated fat (Renaud and de
Lorgeril 1992).

Cis resveratrol

trans resveratrol

Figure 2.5. Structures of cis resveratrol and trans resveratrol.
Positions denoted with numbers are sites of glucuronidation and/or sulfation in
biological matrices.

Food source Resveratrol is found in over 72 plants species but the primary dietary
sources are grape derived products including selected juices and red wines, dark
chocolate, select berries, pistachio, peanuts and peanut products (King, Bomser et al.
2006; Fernandez Marin, Mateos et al. 2012). The concentration of resveratrol present in
products is dependent on several factors such as cultivar, climate, geographic region
and also different components of a fruit. For example, the content of trans resveratrol
in different red wines were reported to range from undetectable to 14.3mg/L (Stervbo,
Vang et al. 2007; Fernandez Marin, Mateos et al. 2012) while others reported to range
from 0.1 to 15mg/L (Fremont 2000). As an example of the variability of resveratrol
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content in different components of fruit, resveratrol is found in the seed and skin of
grapes but not in flesh and therefore, relatively high concentrations were found in red
wine fermented with flesh and skin while white wine which uses only the flesh of the
grape had little or no resveratrol (King, Bomser et al. 2006).
The dietary intake of flavonoids are low as 100mg/d as discussed previously. The
major food sources contain low levels of flavonoids: <50mg/100g food weight (USDA
2003). Since the dietary levels of flavonoids are so low, it is reasonable to increase the
intake with dietary supplements where these can be shown to have health benefits.
According to World Health Organization (WHO), ~80% of the world population use
botanicals for health. About 42% of population in the United States claimed to have
used botanical dietary supplements to improve health status (Khan and Smillie 2012).
The increasing prevalence polyphenol supplement use has resulted a huge revenue
increase for the dietary supplement industry to $4.8 billion in 2008 compared to only
$2.9 billion in 1995 (Khan and Smillie 2012). However, one botanical plant may contain
different compounds and many of them could contribute to the health benefits. In order
to gain more insights on the specific bioacatives responsible for their neuroprotective
actions, more studies need to be conducted to identify the active compounds in foods
as well as the dietary effects. The studies discussed in this dissertation were designed
based on the idea described here aiming to identify the bioavailability of polyphenols
from grape derived extracts and from some other commonly consumed fruit extracts.
The popularity of botanicals on their therapeutic effects warrant the investigation on
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the absorption and metabolism of polyphenol rich botanicals to further support the
usage of dietary supplements of naturally occurred botanicals for general health.

2.2

Food Matrix and Polyphenol Bioavailability

Many factors have been suggested to influence the absorption of flavonoids including
insufficient absorption in gastrointestinal tract, interaction with the food matrix and the
influences of food processing (Ferruzzi 2010). We focus in this section on the interaction
of flavonoids and food matrix since we are interested in the impact of high fat
diabetogenic diet on polyphenol absorption. There have been many studies conducted
to understand the interaction of protein and polyphenols absorption (see review in
(Bandyopadhyay, Ghosh et al. 2012) and (Ferruzzi 2010)). However, there has been very
few investigation of the effects of fat content on polyphenol absorption. When
searching Pubmed with key words combinations of ‘fat content’, ‘polyphenol
absorption’, ‘bioaccessibility and bioavailability’, there was only one study that
investigated the effect of fat content on cocoa polyphenol bioaccessibility in an in vitro
digestion model (Ortega, Reguant et al. 2009). They showed that high fat content in
cocoa liquor protected catechins during digestion and therefore demonstrated better
uptake in the enterocytes. The lack of data on how fat content can influence polyphenol
absorption is possibly due to the hydrophilic nature of flavonoids (Scholz and Williamson
2007) and therefore, their interaction with fat to form micelles is limited. It is necessary
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to obtain data on the impact of fat content on polyphenol absorption since fat is the
major fraction in modern western diet.

2.3

Polyphenols and Neurodegenerative Diseases

Increasing evidence suggests that plant derived polyphenols play an important role in
improving cognitive functions and preventing/delaying the onset of certain
neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease and
Huntington’s disease. Our project specifically focused on Alzheimer’s disease since it is
the most common neurological disorder affecting 18 million worldwide and estimated
to reach 34 million by 2025 (Mount and Downton 2006). The association between
polyphenol consumption and lower AD risk is based on several epidemiological studies.
A prospective study published in 1997 in the Bordeaux area in France concluded that
moderate wine consumption (3 to 4 glasses per day) negatively correlated to AD risk
(Orgogozo, Dartigues et al. 1997). The Copenhagen City Heart study concluded that
monthly and weekly wine consumption was associated with a lower risk of dementia,
however, the volume of the drinks was not specified (Truelsen, Thudium et al. 2002).
Many prospective studies subsequently confirmed a negative relationship between
flavonoids intake and incidence of dementia or AD. For example, the Letenneur group in
the Personnes A’gees Quid study concluded that high flavonoid intake (the highest
quartile: 17.7 – 36.94 mg/d) correlated with better cognitive ability over a 10 year
tracking period (Letenneur, Proust Lima et al. 2007). Scarmeas and colleagues published
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a series of studies validated the relationship between a Mediterranean diet and risk for
AD (Scarmeas, Stern et al. 2006; Scarmeas, Stern et al. 2009). In 2006, they concluded
that higher adherence to the Mediterranean diet is associated with a lower risk for AD in
a community based study conducted in New York City with a 4 year follow up (Scarmeas,
Stern et al. 2006). In 2009, they further concluded that higher adherence to
Mediterranean diet also reduced risk of developing mild cognitive impairment which
later progress to AD in a similar setting to the previous report in 2006 (Scarmeas, Stern
et al. 2009). Although there is still significant debate on the potential benefits of
polyphenol with regard to age related diseases, evidence appears to be growing for
these plant derived compounds as promising dietary/supplemental neuroprotective
agents.

2.3.1 Type II Diabetes and Alzheimer’s Disease
Due to the multifaceted nature of AD, the primary cause and pathways to a cure for
AD remain elusive. Researchers have focused on possible factors such as genetics,
nutrition and lifestyle that may influence the risk for AD to prevent as well as to develop
strategies for treatment of AD. Among all the metabolic disorders, type II diabetes
disturbs systemic and central metabolic functions which directly influences glucose
metabolism in brain (Kahn, Hull et al. 2006). The relationship between type II diabetes
and AD has been documented, but remains controversial. For example, researchers
found a two fold increase in risk for AD in men with diabetes and ~1.5 fold in diabetic
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women compared to the non diabetics in a cohort in Rochester, MN (Leibson, Rocca et
al. 1997). The Rotterdam study yielded similar results that diabetic patients had two
times higher risk for dementia and AD (Ott, Stolk et al. 1999). A review by Cukierman et
al. summarized 25 prospective studies with more than 8656 people with diabetes in a
follow up period ranged from 2 to 18 years and the authors found a 1.5 fold increase in
risk for cognitive decline and a 1.6 fold greater risk of future dementia in diabetics
compared to the non diabetics (Cukierman, Gerstein et al. 2005). Recently, a studied
employed MRI to determine grey matter volume in a middle aged cohort and found that
the level of insulin resistance positively correlated with brain atrophy (Willette, Xu et al.
2013). The strong correlation between type II diabetes and AD suggest that type II
diabetes may in fact play a role in onset or progression of this disease. Therefore, the
impact of type II diabetes on polyphenol bioavailability and metabolism should be
better understood.

2.3.2 Mechanism of Action of Polyphenols in Alzheimer’s Disease
There is considerable evidence for the benefits of polyphenol rich foods and dietary
supplements in the prevention of age related neurodegenerative diseases (see review in
(Ebrahimi and Schluesener 2012). While specific mechanisms remain elusive, it has been
proposed that protection of age related diseases by polyphenols may be due, in part, to
their properties of antioxidants, increase of nitric oxide production and anti
inflammation mechanisms (Campos Esparza Mdel and Torres Ramos 2010; Albarracin,
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Stab et al. 2012). It has been proposed that neuroinflammation and neurotoxicity are
the two major causes of neuronal dysfunction. Each of them includes several toxic
phenomena which play important roles in Alzheimer’s disease pathogenesis. These toxic
phenomena are also the important targets for polyphenols in the prevention of most
neurodegenerative disease which will be described in the following paragraphs.
Neuroinflammation Inflammation is a defense response of cells to insults like toxins,
tissue injuries or A in neuroinflammation. The transient neuroinflammation response
starts with microglia activation. Activated microglia function as macrophages in the
central nervous system (CNS) but engulfing A by phagocytosis (Querfurth and LaFerla
2010) or binding A by the receptor for advanced glycation endproducts (RAGE) (Gu,
Kelm et al. 2004). Prolonged A insults result in long term microglia activation which
induces the release inflammatory mediators including chemokines and cytokines such as
IL 1 , IL 6, TNF

and chemokine IL 8. Release of inflammatory cytokines induces more

microglia activation which eventually results in neuronal cell death (Lee, Rizer et al.
2010). The astrocyte is another key player in the neuroinflammatory process. Astrocytes
have been show to express RAGE which bind A and further degrade A (Wyss Coray,
Loike et al. 2003). A study showed that activated astrocytes induced by A also release
chemokines and cytokines which promote neuron death (Smits, Rijsmus et al. 2002).
Overall, when facing A attacks, microglia and astrocytes work together on A clearance
and degradation. However, ineffective A clearance leading to the release of
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inflammatory mediators is thought to be the dominant process, leading to the
accelerated development of AD (Fiala, Lin et al. 2005).
Neuroinflammation results in an increase in nitric oxide, and cytokine production.
These processes are enhanced by the presence of APO 4 genotype. Polyphenols
modulate neuronal dysfunction by targeting these mechanisms which contribute to
neuroinflammation. It has been demonstrated that quercetin inhibits
neuroinflammation by decreasing nitric oxide and cytokine production in microglia
(Sharma, Mishra et al. 2007; Bureau, Longpre et al. 2008; Kao, Ou et al. 2010). Catechin
and epicatechin were shown to prevent TNF

release in primary glial cells at a

physiological relevant doses (10 300 nM) (Vafeiadou, Vauzour et al. 2009). Blueberry
polyphenols were shown to inhibit nitric oxide, IL 1 and TNF

production induced by

lipopolysacharides in microglia cells (Lau, Bielinski et al. 2007).
Neurotoxocity – Neurotoxinic mechanisms such as oxidative stress, protein
phosphorylation, protein aggregation are thought to contribute to neuropathogenesis.
The health benefits of polyphenols are thought to be due to their free radical scavenging
capacity imparted by the phenol structure of the flavonoid backbone (Visioli, Bellomo et
al. 1998; Russo, Acquaviva et al. 2000; Halliwell 2006). Recently this hypothesis has been
challenged due to extremely high concentrations of polyphenols are required to show
desired benefits {Williams, 2004 #85}. A high plasma or tissue concentration of
polyphenols often times is difficult to achieve in vivo due to the low bioavailability and
high excretion rate of most dietary polyphenols. Therefore, although polyphenols have
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antioxidants capacity, their potential impact may be reduced due to low bioavailability
(Williams, Spencer et al. 2004). In the case of Alzheimer’s disease, tau protein
phosphorylation is thought to contribute to neurodegeneration. The normal function of
tau is to stabilize microtubules of neurons. However, hyperphosphorylated tau protein
has low infinity to microtubules and therefore easily self assembled (Ballatore, Lee et al.
2007). Aggregation of hyperphosphorylated tau form neurofibrillary tangles (NFTs)
which are toxic and can lead to neuron death (Roy, Cohen et al. 2005). It has been
suggested that polyphenols may inhibit tau protein aggregation. For example, grape
polyphenols has been shown to attenuate tau neuropathology in a transgenic
Alzheimer’s mouse model (Wang, Santa Maria et al. 2010). EGCG has been shown to
modulate tau pathology in a transgenic Alzheimer’s mouse model (Arendash, Mori et al.
2009).
Protein aggregation is another toxic phenomenon that play an important role in AD
pathogenesis. A is thought to be the cause to neuronal loss which leads to dementia
and other neurodegenerative disorders. A is a peptide with 40 or 42 amino acids. A 42
with hydrophobic amino acids at the sequence tail induce cell death due to this unique
chemical structure .A peptides first form soluble prefibrillar oligomers and further
aggregate to prefibrillar oligomers and to fibrils and finally to insoluble plaques (Sakono,
Zako et al. 2008). Prefibrillar oligomers are considered to be more toxic than plaques
(Caughey and Lansbury 2003; Ferreira, Vieira et al. 2007). There is mounting evidence
that polyphenols inhibit A deposition decreasing AD pathology in in vivo or in vitro
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models. For example, grape seed extracts consumption has been shown to prevent A
deposition in the brain of Alzheimer’s disease mice (Wang, Thomas et al. 2009).
Polyphenols in Cabernet Sauvignon have been shown to inhibit A aggregation in am AD
mouse model (Ho, Chen et al. 2009).

2.3.3 Type II Diabetes and Polyphenol Metabolism
Type II diabetes is known to alter key endogenous hormone secretion including
insulin and glucagon (Samsom, Vermeijden et al. 2003). Insulin resistance and
hyperglycemia lead to changes in expression of certain phase II metabolizing enzymes
(Kim and Novak 2007). For example, researchers showed increased gene expression of
UDP glucuronosyltransferase (UGT 1A1) in a diabetes rat model (Tunon, Gonzalez et al.
1991; Braun, Coffey et al. 1998) but decreased of sulfotransferase (SULT) 2A1 (Runge
Morris and Vento 1995). Polyphenols are substrates for UGT and SULT during
glucuronidation and sulfation process and therefore, disturbance in enzyme gene
expression might lead to changes in generation of biologically relevant polyphenol
metabolite levels. Some of the most common complications of type II diabetes are
gastrointestinal (GI) symptoms such as vomiting, constipation, and diarrhea (Feldman
and Schiller 1983). The GI irregularities were thought to be due to abnormal GI motility
in diabetic patients. Feldman et al. demonstrated that diabetic patients had delayed
gastric empty compared to non diabetics (Feldman and Schiller 1983). The delayed
gastric emptying of liquid and solid foods was later validated by other researchers
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(Horowitz, Edelbroek et al. 1991; Samsom, Vermeijden et al. 2003). Delayed gastric
emptying may influence oral drug absorption (Horowitz, O'Donovan et al. 2002) and
therefore, possibly affect polyphenol absorption and bioavailability. Considering the
strong link between metabolic dysfunction in type II diabetes and neurodegenerative
diseases, it is important to understand the impact of diabetic condition on polyphenol
bioavailability and metabolism in order to develop optimal dosing strategies for
prevention or therapy.

2.4

Polyphenols and Brain Development in Infants and Children

Evidence for the benefit of polyphenols rich foods and dietary supplements in
prevention of age related neurodegenerative diseases is substantial (Ebrahimi and
Schluesener 2012). Two plausible underlying mechanisms have been previously
discussed. With underlying mechanisms of protection also related to
improvement/preservation of cognitive function, interest in the application of similar
polyphenols to promote healthy brain and cognitive development in young population
has grown. However, few studies exist on polyphenol benefits in young populations.
Most investigations have focused on prenatal diseases when addressing the beneficial
effects of polyphenols in early life. For example, Loren et al. showed that maternal
supplementation with pomegranate juice protected against hypoxic ischemic injury in
rat pup’s brains (Loren, Seeram et al. 2005). Narita et al. demonstrated that grape seed
extract protected glutamate induced insults in a primary neonatal mouse neuron
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culture (Narita, Hisamoto et al. 2011). Few have discussed the effects of polyphenols on
healthy normal neurons. After searching in PubMed with the combination of key words
like ‘polyphenol’, ‘neonate’, ‘young’, ‘infant’, ‘neuron’, ‘cell growth’, there are only two
papers out of 49 relevant to normal cell growth and polyphenols (Godlewski, Slazak et al.
2006; Han, Lee et al. 2011). Han et al. found that EGCG offered protection to normal
human dermal fibroblasts (Han, Lee et al. 2011). Godlewski et al. reported that boiled
soybeans increased mitotic ratio in the intestinal mucosa of young rats which suggested
faster cell turnover of enterocytes (Godlewski, Slazak et al. 2006). No direct publication
is found under Pubmed search on polyphenols and healthy neuron growth. More
studies are needed to better understand the influences of polyphenols on young
developing brain.

2.5

Polyphenol Absorption, Metabolism and Excretion

After ingestion, polyphenols enter gastrointestinal tract to undergo absorption,
metabolism and excretion. Flavan 3 ols, quercetin and anthocyanins are absorbed
through shared mechanisms but with minor differences due to their chemical structures
which directly influence their potential to circulate in plasma and to reach target tissues.
Their differences in bioavailability may be linked to their ability to influence brain health
and development. Additionally, flavonoids are metabolized extensively leading to the
structural modifications (conjugations) which influence tissue distribution and excretion.
Finally, polyphenols and/or their metabolites are excreted from the body and some can
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be further metabolized in colon by colonic microflora. The following section will discuss
the absorption, metabolism and excretion of flavan 3 ols, quercetin and anthocyanins.
The proposed polyphenol absorption and metabolism mechanism is illustrated in Figure
2.6.

Figure 2.6. Proposed polyphenol absorption and metabolism pathway.

2.5.1 Absorption
Stomach Following oral processing, flavonoids in foods and beverages are digested in
the gastric environment. There is little to no evidence that flavan 3 ols and quercetin
are absorbed in the gastric phase. However, they are believed to be stable in this
environment and begin to be extracted from the food matrix as the digestion of food
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facilitates release of flavonoids (Green, Murphy et al. 2007). Anthocyanins however,
have been shown to be readily absorbed in the gastric environment through the
stomach. It was reported that after 2.7mg of cyanidin 3 glucoside consumption, human
plasma reached 24 nmol within 30 minutes indicating the absorption taken place in the
stomach (Miyazawa, Nakagawa et al. 1999). It was also shown in an anesthetized rat
model that anthocyanin glucosides are absorbed in the stomach (Passamonti, Vrhovsek
et al. 2003). The mechanism on gastric absorption of anthocyanins has been suggested
to involve active transport through the bilitranslocase transporter in the stomach
(Passamonti, Vrhovsek et al. 2002). After absorption intact from the stomach,
anthocyanins (primarily glucosides) move into the blood and are distributed to tissues
(described later). Unabsorbed fraction of anthocyanins and other flavonoids are
emptied into the small intestine where digestion and continues.
Small intestine Unlike other flavonoids usually in glycosylated forms, flavan 3 ols
generally exist as aglycones. Once ingested, flavan 3 ol monomers can be directly
absorbed into enterocytes by active uptake for further transformation (Monagas, Urpi
Sarda et al. 2010). There are two major pathways being suggested for quercetin
glucoside absorption. One pathway is that quercetin 4’ glucoside, quercetin 3 glucoside
and quercetin 3,4’ glucoside were deglycosylated by lactase phloridzin hydrolase (LPH)
in the small intestinal lumen to become quercetin aglycone which further diffuse into
enterocytes by passive transport due to its lipophilic structure in a in vitro model (Day,
Canada et al. 2000). The LPH pathway was also observed in the Caco 2 cell model
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(Murota, Shimizu et al. 2002). The other pathway being suggested was that quercetin
glycosides are transported into the enterocytes by sodium dependent glucose
transporter (SGLT 1) (Hollman, de Vries et al. 1995) and deglycosylated by the cystolic
glucosidase to form quercetin aglycones (Day, DuPont et al. 1998; Crespy, Morand et al.
2001) in rats and humans. It has been shown in a Caco 2 cell model that quercetin
glycosides were the substrates for multi drug resistance protein 2 (MRP2) which are
responsible for effluxing quercetin glycosides out to the intestinal lumen (Walgren,
Karnaky et al. 2000). Based on that observation, the LPH pathway is considered to be
the primary mechanism for quercetin to be absorbed into the enterocytes. After gastric
absorption in the stomach, anthocyanins continue to be absorbed in the small intestine
in a rat model (Talavera, Felgines et al. 2004) and a Caco 2 cell model (Yi, Akoh et al.
2006). There is no consensus in terms of the mechanism as to how anthocyanins are
absorbed. LPH and SGLT 1 pathways similar to quercetin were proposed by Kay et al.
(Kay 2006) which contradicted by the evidence provided by Walton et al. in a mice
model (Walton, McGhie et al. 2006). More studies are needed to gather more data.
Resveratrol was metabolized to form metabolites such as glucuronidated conjugates.
The conjugates are the major forms to be absorbed in the small intestine demonstrated
in a Caco 2 cell model via passive diffusion and SGLT 1 pathways similar to quercetin
(Henry, Vitrac et al. 2005). It was suspected that resveratrol conjugates might be the
substrates for MRP2 which can be effluxed back to the intestinal lumen (Brown, Kroon
et al. 2009). More studies are needed to obtain better understanding.
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2.5.2 Metabolism
After absorption, most flavonoids and stilbenoids undergo chemical changes
following the xenobiotic metabolism. The structure modifications involve three major
conjugation pathways also known as Phase II xenobiotic metabolism in the small
intestine and in the liver. Specifically, glucuronidation, sulfation and methylation
through the actions of uridine 5’ diphosphate glucuronosyltransferases (UGTs),
catechol O methyltransferase (COMT), sulfotransferases (SULT). Flavonoids undergo
these metabolism pathways to become metabolites which circulate in the body and
deposit in the tissue. These metabolites, and not the native plant derived forms, for the
most part, are present in tissues and may play major roles in promotion of health and
protection against chronic diseases in the body and particularly in the brain.
After being absorbed into the enterocytes, flavan 3 ol monomers undergo
metabolism. Small intestine is the main site for glucuronidation catalyzed by UGTs with
UGT1 being the major player in flavonoid glucuronidation process (Vaidyanathan and
Walle 2002). After first pass through small intestinal metabolism, formed conjugates
circulate to the liver via portal vein for further metabolism including methylation by
COMT, sulfation by SULT and glucuronidation. Generally, the hydroxyl groups at 3’ and 4’
position at B ring and 5 and 7 position at A ring are the target for conjugation. It has
been identified in studies that flavan 3 ol monomers can form 5 , 7 and 3’ O
glucuronide, 7 O sulfate, 3’ and 4’ O methyl, or 3’ O methyl 7 O glucuronide, 4’ O
methyl 5 or 7 O glucuronide (Baba, Osakabe et al. 2000; Natsume, Osakabe et al. 2003;
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Spencer, Abd el Mohsen et al. 2004; Schroeter, Heiss et al. 2006). Quercetin
glucuronides were found in an in situ model using small intestinal tissue from rats
(Crespy, Morand et al. 1999) and also in plasma and urine from humans (Meng, Maliakal
et al. 2004). Quercetin sulfates were also found in the in situ model from rat intestine
(Crespy, Morand et al. 1999) and in liver microsomes (de Santi, Pietrabissa et al. 2000)
with the involvement of sulfotransfearses (De Santi, Pietrabissa et al. 2000). The
proposed mechanism on the formation of quercetin glucuronides is that quercetin
glycoside is first hydrolyzed to aglycones and then further metabolized to glucuronides
by UGTs (Radominska Pandya, Little et al. 1998; Aumont, Krisa et al. 2001). UGTs has
been shown to present in the liver, kidney and intestine in humans which explains the
rapid glucuronidation process of polyphenols (Abid, Bouchon et al. 1995; Mojarrabi and
Mackenzie 1998; de Santi, Pietrabissa et al. 2000). Methylated quercetin has been found
in rat plasma and urine after oral consumption of quercetin (Manach, Morand et al.
1995) catalyzed by COMT. Studies found that peonidin monoglucuronide, cyanidin 3
glucoside, cyanidin monoglucuronide and pelargondin monoglucuronide in human urine
after consumption of elderberry or strawberry (Wu, Cao et al. 2002; Felgines, Talavera
et al. 2003). Anthocyanin sulfates were also identified in the same study (Wu, Cao et al.
2002; Felgines, Talavera et al. 2003) and SULTs are thought to be the key enzymes
responsible for generating the sulfate metabolites. Two possible mechanisms of the
formation of anthocyanin glucuronide were proposed to be: 1) anthocyanin glycosides
are directly converted to monoglucuronide by UDP glucose dehydrogenase or are first
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hydrolyzed to aglycons and then glucuronidated (Wu, Pittman et al. 2005). Although not
reported in plasma, methylated anthocyanins are detected in rat livers (Miyazawa,
Nakagawa et al. 1999). Resveratrol glucuronides were identified in human plasma after
oral consumption of resveratrol aglycones (Burkon and Somoza 2008). Resveratrol
glucuronides were proposed to be generated under similar pathway of quercetin
glucuronides which involves aglycones as intermediates to be further glucuronidated
(Aumont, Krisa et al. 2001). Resveratrol mono and disulfates were found in human
plasma after oral consumption of resveratrol (Walle, Hsieh et al. 2004; Boocock, Patel et
al. 2007). SULTs are thought to be responsible for the sulfation of polyphenol during
xenobiotic metabolism (De Santi, Pietrabissa et al. 2000). There is no evidence showing
the presence of methylated resveratrol due to the lack of catechol functional group in
resveratrol structure and therefore disqualified resveratrol to be a substrate for COMT.

2.5.3 Excretion
After absorption and metabolism, polyphenols reach kidney for further conjugation
and are excreted in the urine. Quercetin was reported to have urinary recovery of 0.3%
and 1% in men (Hollman, van Trijp et al. 1997). Typically, anthocyanins have very small
percentage being excreted in the urine in human, about 0.05% to 0.1% (Wu, Cao et al.
2002; Kay, Mazza et al. 2004; Kay, Mazza et al. 2005). Resveratrol was reported to have
relatively high urinary recovery of 26% and 52% in humans (Meng, Maliakal et al. 2004).
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The most appropriate approach to estimate polyphenols absorption is to measure
their bioavailability which is defined as the percentage of a flavonoid that is absorbed
into the bloodstream and available to exert its effect at the target tissue (Ferruzzi 2013).
Bioavailability is measured via a pharmacokinetic study designed to determined plasma
concentration of a flavonoid as a function of time which describe the onset, duration
and intensity of a flavonoid’s effect (Clark 1986). Pharmacokinetic parameters including
the maximum plasma concentration (Cmax), time at maximum plasma concentration
(Tmax) and total plasma concentration over a period of time (AUC0 max) are most
commonly used to represent the absorption pattern of a flavonoid (Clark 1986). There
have been many studies investigating bioavailability of pure flavonoid compounds or
flavonoid rich food on human or animal models. Table 2.5. provides an summary of
bioavailability studies conducted on flavan 3 ols, quercetin, resveratrol and
anthocyanins either in foods or pure compounds.

Table 2.5. Summary of selected bioavailability studies on flavan 3 ols, quercetin, resveratrol and anthocyanins.
Flavan 3 ol

Model

Formulation

Dose

Duration

Treatment

Target
Compound

Goldberg et al.
(2003)

human

catechin in v 8, wine or juice

25mg/70kg bw

acute

oral

catechin
(free and conjugated)

Abd El Mohsen et al.
(2002)

Wistar rats

EC aglycon

100mg/kg bw

acute

gavage

Baba et al.
(2001)

SD rats

EC aglycon

172µmol/kg bw

acute

gavage

Bell et al.
(2000)

human

red wine (120mL)

35mg catechin

acute

oral

Harada et al.
(1999)

Wistar rats

EC aglycon

100mg/kg bw

acute

gavage

Donovan et al.
(1999)

human

red wine (120mL)

35mg catechin

acute

oral

Da Silva et al.
(1998)

Wistar rats

EC aglycon

50mg/200g bw

acute

gavage

Enzymatic extraction method indicates that the samples are treated with
polyphenols into free (aglycone) forms.

EC
3' O MeC
EC glucuronide
3' O MeC glucuronide
4' O MeC glucuronide
EC
EC glucuronide
EC sulfate
EC sulfoglucuronide
methyl EC
methyl EC glucuronide
methyl EC sulfate
methyl EC sulfoglucuronide
Total (methylated,
unmethylated and sulfated)
EC
EC glucuronide
3' O MeC
Total (methylated,
unmethylated and sulfated)
1h, 6h
EC
EC sulfate
EC glucuronide
EC sulfoglucuronide
methyl EC
methyl EC sulfate
methyl EC glucuronide
methyl EC sulfoglucuronide

AUC
(nmol*h/L)
v 8: 0.26 (0 4h)
wine: 0.14 (0 4h)
juice: 1.39 (0 4h)
4500
1220
44640
14400
1160
6480 (0 5h)
39900 (0 5h)
0 (0 5h)
41900 (0 5h)
870 (0 5h)
14900 (0 5h)
41200 (0 5h)
22100 (0 5h)

Cmax
(nmol/L)
0.14
0.13
0.49
blood taken
2h after
sacrifice
one time
point only

Tmax
(h)

Extraction
method

0.5

enzymatic

2

emzymatic

na

1

emzymatic

371 (0 8h)

78

1.5

emzymatic

2610 (0 6h)
37320 (0 6h)
12.24 (0 6h)

1090
15560
3760

2

emzymatic

382 (0 8h)

75

1.5

emzymatic

15900 (0 6h)
3600 (0 6h)
64000 (0 6h)
5400 (0 6h)
1200 (0 6h)
16900 (0 6h)
17400 (0 6h)
51900 (0 6h)

13.3 (1h)
3.6 (6h)
52.1 (1h)
5.4 (6h)

1 or 6

emzymatic

glucuronidase/sulfatase to deconjugate all
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Table 2.5. Continued.
Quercetin

Model

Formulation

Dose

Duration

Treatment

Target
Compound

AUC

Cmax

Tmax

Extraction
method

Goldberg et al.
(2003)

human

quercetein in v 8, wine or juice

10mg/70kg bw

acute

oral

quercetin
(free and conjugated)

v 8: 0.53 (0 4h)
wine: 0.88 (0 4h)
juice: 0.0033 (0 4h)

0.21
0.42
0.16

0.5

enzymatic

human

apple cider

1.6mg quercetin eq.

acute

oral

3' methyl quercetinn

na (0 24h)

140

na

enzymatic

32.1 (0 24h)

7.6

0.68

enzymatic

27.8 (0 24h)

7

0.7

enzymatic

12.6 (0 24h)

2.1

4.3

enzymatic

8.3 (0 24h)

1.1

7

enzymatic

3500 (0 36h)

300

2.5

enzymatic

7700 (0 36h)

740

0.7

enzymatic

3.3 (0 36h)

0.3

9.3

enzymatic

AUC

Cmax

Tmax

Extraction
method

DuPont et al.
(2002)
Graefe et al.
(2001)
Graefe et al.
(2001)
Graefe et al.
(2001)
Graefe et al.
(2001)
Hollman et al.
(1997)
Hollman et al.
(1997)
Hollman et al.
(1997)

Resveratrol

human

onions

100mg quercetin eq.

acute

oral

human

quercetin 4' glucoside

100mg quercetin eq.

acute

oral

human

buckweat tea

200mg quercetin eq.

acute

oral

human

pure rutin

200mg quercetin eq.

acute

oral

human

apple

107mg quercetin eq.

acute

oral

human

onions

68mg quercetin eq.

acute

oral

human

pure rutin

100mg quercetin eq.

acute

oral

Model

Formulation

Dose

Duration

Treatment

Chow et al.
(2010)

human

trans resveratrol

1g resveratrol

acute

oral

Almeida et al.
(2009)

human

trans resveratrol

150mg, 6x/day

day1
day13

oral

Boocock et al.
(2007)

human

trans resveratrol

5g resveratrol

acute

oral

Goldberg et al.
(2003)

human

trans res in v 8, wine or juice

25mg/70kg bw

acute

oral

Biasutto et al.
(2002)

rat

trans resveratrol

0.22mmol/kg bw

acute

gavage

Marier et al.
(2002)

SD rats

trans resveratrol

50mg/kg bw

acute

gavage

quercetin
(free and conjugated)
quercetin
(free and conjugated)
quercetin
(free and conjugated)
quercetin
(free and conjugated)
quercetin
(free and conjugated)
quercetin
(free and conjugated)
quercetin
(free and conjugated)

Target
Compound
resveratrol
res sulfoglucuronide
res monoglucuronide 1
res monoglucuronide 2
res disulfate
res 3 sulfate
trans res
resveratrol
res glucuronide 1
res glucuronide 2
res 3 sulfate

resveratrol
resveratrol
res sulfate
res glucuronide
res disulfate
resveratrol
res glucuronide

140
346

72.2
339.6
619.5
767
359.3
2376.6
109
280

5785
43521
37916
135517
v 8: 0.073 (0 4h)
wine: 0.076 (0 4h)
juice: 0.078 (0 4h)
1100
2400
35500
14400
7000 (0 12)
321900 (0 12)

na

only 1h time
not mentioned
point

0.8 1.5

SPE

2359
5635
7609
18833

1.5
2
2.5
2.05

SPE

0.037
0.031
0.035

0.5

enzymatic

1200

1

SPE

6570
105000

0.29
0.42

enzymatic
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Table 2.5. Continued.
Anthocyanidins
Neilson et al.
(2003)
Neilson et al.
(2003)

Model

Formulation

Dose

Duration

Treatment

Target
Compound

human

black currant juice

19.7 mg total antho/kg bw

acute

oral

total ac

rabbit

black currant juice

117mg total antho/kg bw

acute

gavage

AUC
19 (0 4)

total ac

13.4 (0 4)

Dp 3 glucoside
Dp 3 rutinoside
Cy 3 glucoside
Cy 3 rutinoside
Dp 3 rutinoside
Cy 3 rutinoside
Dp 3 glucoside
Cy 3 glucoside
Dp 3 rutinoside
Cy 3 rutinoside
Cy 3 glucoside

7.2 (0 6)
40.8 (0 6)
4.1 (0 6)
40.9 (0 6)
287.9 (0 8)
167.6 (0 8)
68.8 (0 8)
9.1 (0 8)
1330 (0 8)
2540 (0 8)
1510 (0 8)

Cmax

Tmax

Extraction
method

32 107

0.75

SPE

2

0.5

SPE

3.1 51

1

enzymatic

73.4
46.3
22.7
5
580
850
840

1.75
1.5
1.5
1.25
2
0.5
0.5

Rechner et al.
(2002)

human

black currant juice (330 mL)

1g total antho

acute

oral

Matsumoto et al.
(2001)

human

black currant extract

3.58mg total antho/kg bw

acute

oral

Matsumoto et al.
(2001)

Wistar rats

black currant extract

800 mol/kg of bw

acute

gavage

human

elderberry juice (spray dried)

720mg total antho/kg bw

acute

oral

total ac

na

97

1.1 1.2

SPE

human

blueberry (freeze dried)

1.2g total antho

acute

oral

total ac

41.4 (0 4)

13.09

4

SPE

human

red wine (500 mL)

68mg Mv 3 glucoside

acute

oral

Mv 3 glucoside

288

1.38

0.83

enzymatic

human

red grape juice

117mg Mv 3 glucoside

acute

oral

Mv 3 glucoside

662

3

1.5

enzymatic

human

red fruit extract (1.6g)

2.7mg Cy 3 glucoside/kg bw

acute

oral

Cy glucoside

na

29

1

SPE

SD rats

red fruit extract

320mg Cy 3 glucoside/kg bw

acute

gavage

Cy glucoside

3.6 (0 4)

7.8

0.25

SPE

Cao et al.
(2001)
Mazza et al.
(2001)
Bub et al.
(2001)
Bub et al.
(2001)
Miyazawa et al.
(1997)
Miyazawa et al.
(1997)

SPE

SPE
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2.6

Tissue Distribution of Polyphenols

Low bioaccessibility and bioavailability in gastrointestinal tract (GI) leave flavonoid
metabolites to circulate in low concentrations ranging from µM to nM depending on the dose
and the specific nature of the phenolics. Level of tissue distribution is even less well known for
flavonoids after GI absorption and excretion. Data on storage tissue has been identified for
flavonoid metabolites and their presence in tissues is considered to be transient (El Mohsen,
Marks et al. 2004; Tsang, Auger et al. 2005; El Mohsen, Marks et al. 2006; Juan, Maijo et al.
2010). However, the general notion remains that these bioactive flavonoids must reach target
tissues to provide specific protective benefits. This requirement poses a hurdle in the case of
neuroprotective polyphenols due to the difficulties in crossing the blood brain barrier.

2.6.1 Blood Brain Barrier and Efflux Transporters
The blood brain barrier is a structure consisted of endothelial cells to form the walls of
capillaries. The tight junctions between the endothelial cells regulate the exchange of
nutrients and function as a protective barrier for toxins (Abbott, Patabendige et al. 2010).
Polyphenols are considered xenobiotics and undergo phase I and II xenobiotic metabolism as
described previously. Their xenobiotic properties make them substrates to many efflux
transporters responsible for gate keeping at the blood brain barrier. The most studied efflux
transporters are ATP binding cassette transporters which include p glycoprotein, multidrug
resistance associated proteins and breast cancer resistance protein. Youdim et al. conducted
a series of studies to investigate flavonoid permeability across blood brain barrier using in
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vitro (ECV/304C6 coculture) cell model. They demonstrated that flavonoid permeability
dependent on their lipophilicity and polarity. Compounds are less polar (i.e. O methylated
conjugates) have better permeability than more polar ones (i.e. sulfated and glucuronidated
conjugates) (Youdim, Dobbie et al. 2003). They further demonstrated that flavonoids are the
substrates of p glycoprotein and the permeability dependent on their interaction with efflux
transporters (Youdim, Qaiser et al. 2004). More recently, Faria et al. demonstrated that
stereoselectivity (epicatechin >> catechin) is also a determining factor for brain permeability
(Faria, Pestana et al. 2011). These in vitro studies sparks the interests in more in vivo studies
investigating brain concentrations of polyphenols to support their neuroprotective properties.
However, to date only a few studies have documented the presence of polyphenols in brain
tissues.

2.6.2 Current Evidence of Polyphenol Deposition in Brain Tissue
In order to fill the gap of knowledge on brain accumulation of polyphenols, a summary of
current data is generated in Table 2.6. to illustrate the knowledge up to date including the
basic parameters on the study design (species, dose, formulation and etc.). Based on what we
have known here, our research was designed to fill the gap of what is unknown including the
effects of diet composition (Chapter 3), disease condition on polyphenol brain deposition
(Chapter 4) and also the regional brain deposition differences of polyphenols (Chapter 5).

Table 2.6. Summary of current data on favan 3 ols, quercetin, resveratrol and anthocyanin deposition in brain tissues.
Flavan 3 ol
Serra et al.
(2012)
Ferruzzi et al.
(2009)
Prasain et al.
(2009)
Chu et al.
(2007)
Abd El Mohsen
(2002)
Suganuma et al.
(1998)
Nakagawa and Miyazawa
(1997)

Quercetin
Ho et al.
(2013)
Ishisaka et al.
(2011)
Rangel Ordonez et al.
(2010)
Huebbe et al.
(2010)
Bierger et al.
(2008)
de Boer et al.
(2005)
de Boer et al.
(2005)
Mullen et al.
(2002)

Dose

Duration

Treatment

Harvest
Approach

Time at harvest

procyanidin extarct (PE)

50mg PE

acute

oral

NA

4h

SD rats

grape seed extract

50 100mg/kg bw
dose escalation

SD rats

grape seed extract

Model

Formulation

Wistar rats

Target
Compound
MeC sulfate

Brain
Conc.

unit

Extraction

6.4

nmol/g, 4h

SPE

290.7
576.7
53.16
NA
Cmax=0.7
Cmax=38.9

pg/g

enzymatic

ng/g

enzymatic

pmol/g

SPE

<LOQ

NA

enzymatic

SD Dam >
fetal organs

green tea extract

550 mg/kg bw

acute at 15.5d
of gestation

Wistar rats

EC aglycon

100mg/kg bw

1d

gavage

perfusion

immediately

C+3'OMeC
EC+3'OMeEC
C
EC
C
EC
EC glucur
3'Me EC glucur

CD 1 mice

(3H)EGCG

0.05%

actue

gavage

NA

NA

(3H)EGCG

17.3X103

dpm/g

NA

SD rats

EGCG

500mg/kg bw

acute

gavage

perfusion

1h

EGCG

0.5

nmol/g

liquid

Model

Formulation

Dose

Duration

Treatment

Harvest
Approach

Time at harvest

Extraction

Cabernet sauvignon

150 mg tp/kg bw

10d

gavage

perfusion

1h

pmol/g

SPE

Wistar rats

Q aglycon

1%

1 mo

diet

perfusion

1h

Brain
Conc.
0.91
NQ
40.1
47.7

unit

SD rats

pmol/g

enzymatic

SD rats

Ginkgo biloba

600mg/kg bw
600 mg/kg bw

acute
8d

gavage

rinse

immediately

nd
161

ng/g

enzymatic

C57BL/6J mice

Q aglycon

2g/kg diet

6wks

diet

NA

NA

Target
Compound
Q 3 O glucur
Me Q glucur
Q aglycon
MeQ
actue:Q aglycon
acute:MeQ
8 d:2x increae in MeQ
Q aglycon
MeQ

0.28
0.08

nmol/g

enzymatic

pig

Q aglycon

50mg/kg bw

4 wks

diet

NA

1 1.5h

Q aglycon

0.02

nmol/g

enzymatic

Fisher 344 rat

Q aglycon

1%
(500 800 mg/kg bw)

11wks

diet

NA

NA

Q aglycon

0.06

nmol/g

enzymatic

pig

Q aglycon

500mg/kg bw

3d

diet

NA

NA

Q aglycon

0.22

nmol/g

enzymatic

acute

with feed

perfusion

1h

[2 14C]Q 4' glucoside

0

03/g/ml fresh

NA

watt Hooded Lister

[2 14C]Q 4' glucoside

10d

gavage

perfusion

300 mg/kg bw

2x/day for 3d

gavage

perfusion

4h

gavage

rinse

C: Tmax=0.5 h
EC: Tmax=0.5 h

5

58.5x10 dpm

1h

NA: not available.
SPE: Solid phase extraction
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Table 2.6. Continued.
Resveratrol

Model

Formulation

Dose

Duration

Treatment

Harvest
Approach

Time at harvest

Lin et al.
(2012)

SD rats

Polygonaceae

4g/kg bw

2x/d, 7 does

gavage

perfusion

30min

Juan et al.
(2010)
Vingtdeux et al.
(2010)
Abd El Mohsen et al.
(2006)

SD rats

trans res

SD rats

trans res

SD rats

[3H]trans resveratrol

Anthocyanidins

Model

Formulation

Ho et al.
(2013)

SD rats

Del Bo et al.
(2010)

SD rats

15mg/kg bw
100 400 mg/kg bw
dose escalation
50mg/kg bw
1.85 Mba(3H)trans res

acute

i.v.

NA

30min

3 days

gavage

perfusion

1h

?

gavage

acute

2 or 18h

Dose

Duration

Treatment

Harvest
Approach

Time at harvest

Cabernet sauvignon

150 mg tp/kg bw

10d

gavage

perfusion

1h

blueberry

8% in diet

4 or 8wks

diet

perfusion

NA

Target
Compound
Res glucur
Res sulafte
trans res
res glucur
res sulfate

Brain
Conc.

unit

Extraction

ND

NA

enzymatic

0.17
ND
0.04

nmol/g

liquid

res aglycon

1.7

nmol/g

SPE

(3H)trans res

2h:0.03% of oral dose
18h:0.01% of oral dose

NA

NA

Target
Compound
Mv glucoside
Mv glucopyruvate
Mv glucur

Brain
Conc.
12.3 ± 3.85
6.4 ± 5.2
ND

unit

Extraction

pmol/g

SPE

NA

SPE

nmol/kg

SPE

NA

SPE

native forms

ND
cortex:0.7
midbrain:0.92
cerebellum:0.87
detected in cortex and
cerebellum only%

Milbury and Kalt
(2010)

pigs

blueberry

2% in diet

8wks

diet

rinse only

0.5h

native forms and glucur

Kalt et al.
(2008)

pigs

blueberry

1 or 2 or 4%

4wks

diet

rinse only

0.5h

native forms

Abd El Mohsen et al.
(2006)

SD rats

pelargonidin

50 mg/kg bw

acute

gavage

perfusion

2h

pelargonidin aglycon

0.16

nmol/g

SPE

NA

SPE

Andres Lacueva et al.
(2005)
Talavera et al.
(2005)
Passamonti et al.
(2005)

F334 rats

blueberry

2%

10wks

diet

blood free

NA

native forms

ND in
cortex
hippocampus
cerebellumn
striatum

Wistar rat

blackberry

15g/kg bw

15d

diet

perfusion

3h

cy 3 glc

0.21 + 0.05

nmol/g

SPE

Wistar rat

red grape extract

8mg/kg bw

acute

gavage

rinse

10min

native forms

192.2 + 57.5

ng/g

SPE
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2.7

Objectives and Hypotheses

While the neuroprotective benefits of polyphenols are promising, a key step in
understanding the potential of these plant derived compounds to promote healthy
brain development and neurodegenerative processes is the determination of dose
response, bioavailability, metabolism and brain tissue distribution of specific polyphenol
forms. However, limited data exists on 1) brain accumulation concentrations of
polyphenols, 2) the estimation of polyphenol intake on infants and children and 3)
factors that influence polyphenol bioavailability. The following hypotheses are
formulated to provide better understanding regarding these questions.
Hypothesis I: Diabetogenic diet and diabetic condition will influence polyphenol
absorption and brain deposition.
Specific aim 1A: To investigate the impact of diet composition especially the
diabetogenic diet high in fat on central and peripheral polyphenol bioavailability in a
Sprague Dawley rat model.
Specific aim 1B: To investigate the effects of diabetic condition on central and peripheral
polyphenol bioavailability in a Zucker diabetic fatty rat model.
Since dietary pattern has been shown to influence the susceptibility to
neurodegenerative diseases. It is important to understand the effect of dietary fat
especially diabetogenic diet on brain and plasma polyphenol bioavailability in order to
better connect the risk of neurodegeneration with dietary pattern. Follow on that
concept, chronic diabetogenic fat increase risk to type II diabetes. In order to study how
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diabetogenic diet and disease condition impacts on polyphenol absorption, Sprague
Dawley and Zucker diabetic rats models will be used to carried out the studies.
Hypothesis II: Polyphenols metabolites will distributed differentially in brain regions.
Specific aim 2: To explore the regional brain bioavailability of polyphenols from
apple/GSE and bilberry extract in a young swine model.
There is no known data on regional deposition of polyphenols in brains. This aim seeks
to determine the regional differences on key polyphenol metabolites from apple/GSE
and bilberry extract at a pharmacological (82.5 mg/kg body weight) or physiological
(27.5 mg/kg body weight) dose in pig brain. We hypothesize that polyphenol
metabolites will distributed differentially in brain regions.
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CHAPTER 3. PLASMA BIOAVAILABILITY AND BRAIN DISTRIBUTION OF GRAPE
POLYPHENOLS IN SPRAGUE DAWLEY RATS FED ON HIGH FAT DIET

As a part of manuscript titled ‘Role of Standardized Grape Polyphenol Preparation as a
novel treatment to improve synaptic plasticity through attenuation of features of
metabolic syndrome’ submitted to Nutrition & Metabolism

Abstract
Consumption of grape derived polyphenols is associated with the prevention of
neurodegenerative diseases such as Alzheimer’s disease (AD). High fat diet (HF), on the
other hand, has been shown to be a risk factor on AD onset and progression. To further
understand the physiological impacts of polyphenol rich compounds ingested as a grape
polyphenolic preparation termed ‘Standardized Grape Polyphenol’ (SGP) and the
influence of dietary fat on absorption and metabolism of flavan 3 ols, flavonols and
anthocyanins, studies were conducted with Sprague Dawley (SD) rats fed on HF
(60%kcal%fat) or control diet (10%kcal%fat). Rats were randomly assigned to four
groups: control (CNTL) diet water, HF diet water, CNTL diet SGP, HF diet SGP. Animals
were fed on individual diet for 2 weeks prior to water or SGP treatment. Plasma
pharmacokinetics was determined after SGP or water dosing for 10 days. LC MS/MS
analyses confirmed the detection of catechin 5 glucuronide (C 5 glucur), epicatechin 5
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glucuronide (EC 5 glucur), 3’ O methylcatechin 5 glucuronide (3’ OMeC 5 glucur), 3’ O
methylepicatechin 5 glucuronide (3’ OMeEC 5 glucur), quercetin 3 glucuronide (Q 3
glucur), methylquercetin glucuronide (MeO Q glucur) and resveratrol 3 glucuronide
(Res 3 glucur) to be the main metabolites in plasma and brains from repeated SGP
treatment regardless the diet difference. Anthocyanins were detected in plasma and
brains following 10 days of SGP treatment regardless fat content in the diet. These data
illustrate that dietary fat content had minimal influences on plasma bioavailability of
polyphenols from SGP. SGP polyphenol access to the brain was also not influenced by
fat content in the diet.

3.1

Introduction

Excessive fat consumption has become a major concern in the United States and
worldwide. HF consumption has been associated with high incidence of obesity,
dyslipidemia and other systemic metabolic dysfunction that were defined as metabolic
syndromes (Scarpellini and Tack 2012). According to the dietary reference intake (DRI)
report on macronutrient published by National Academy of Science in 2002, the
adequate intake (AI) of total fat is recommended as 30 g/d for all age groups (IOM 2002).
However, the NHANES data reported that during the period of 2009 2010, the mean
amount of total fat consumed by adult Americans was 93.3 g/men and 66.0 g/women
(U.S. Department of Agriculture 2012). This data suggests that U.S. adults consume
about 2 to 3 times over the recommended fat amount. Habitual HF intake is therefore a

47
key contributor to obesity which extends to metabolic syndromes and more severely,
complications of type II diabetes. Furthermore, epidemiological studies have
demonstrated a clear link between obesity and neuro cognitive disorders. For example,
people with obesity possessed a four times higher risk for AD (Pasinetti, Wang et al.
2011). In fact, HF consumption as a precursor of metabolic syndromes may be
considered a factor that places individuals at risk for AD. It is evident that type II
diabetes is associated with high risk to AD (Ott, Stolk et al. 1996; Stolk, Breteler et al.
1997; Craft and Watson 2004). It has been shown in Tg2576 mice, a mouse model of AD,
the diabetogenic diet composed of 60% fat as lard that the diet promoted

amyloid

plaque burden in the brain of the AD mice (Pasinetti, Wang et al. 2011). This result
suggested that HF diet promotes AD but raised another question as to how the HF
influences absorption and metabolism of protective polyphenols from the diet. Our
interest in development of dietary AD preventative strategies based on grape
polyphenols, it is critical to understand the impacts of HF diet on grape polyphenol
absorption and metabolism. These data will provide critical information in determining
the dosage for future efficacy testing on habitual HF consuming population who also are
at high risk of AD.
We have previously demonstrated the bioavailability and brain distribution of Q
metabolites resveratrol and anthocyanins from SD rats repeatedly treated with Concord
grape juice (unpublished), resveratrol (Marambaud, Zhao et al. 2005) and GSE (Wang,
Ho et al. 2008; Ferruzzi, Lobo et al. 2009) individually. Efficacy evidence on individual
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GSE and resveratrol on ameliorating AD have been demonstrated in vitro and in vivo in a
AD mouse model (Marambaud, Zhao et al. 2005; Wang, Ho et al. 2008; Wang, Thomas
et al. 2009). Considering these products provide distinctly different polyphenol classes
(GSE – flaval 3 ols; Concord grape juice – anthocyanins and quercetin; Stilbenoid –
resveratrol) that each target different molecular mechanism related to AD. There is
interest in devising combination strategies favoring delivery of these polyphenols to
brain tissues. However, combination treatments can alter absorption and metabolism of
individual polyphenols. We, therefore, propose to investigate the absorption profile and
tissue distribution of polyphenols from a combination of grape products termed SGP
using a SD rat model. Given the close relationship between HF consumption and AD, the
effect of HF diet on SGP plasma bioavailability and brain distribution was investigated.

3.2

Materials and Method

Chemicals and Materials.
(+) C, ( ) EC, Q 3 glucoside, Q 3 glucur and Q aglycon standards were purchased from
Sigma Chemical Co. (St. Louis, MO). All extraction and LC solvents were HPLC certified
and were obtained from J.T. Baker (Phillipsburg, NJ). GSE Meganatural® AZ powder was
from Polyphenolics (Madera, CA). 100% Concord grape juice (Welch’s) was loaded onto
C18 Solid Phase extraction cartridges (1 c.c.) and washed with ddH2O (0.01% HCl) to
remove sugar. Polyphenols were then eluted with MeOH (0.01% HCl). MeOH was then
removed under vacuum and resulting concentrate was kept frozen until use. trans
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resveratrol, malvidin (Mv) 3 glucoside chloride and cyanidin (Cy) 3 glucoside chloride
were purchased from ChromaDex (Irvine, CA).

Animal and Diet.
Animal studies were conducted under guidance and with protocols approved by the
Purdue University Animal Care and Use Committee. Bioavailability of SGP polyphenols
including anthocyanins, monomeric flavan 3 ols and Q were assessed in a male SD rat
model as described by Ferruzzi et al. (Ferruzzi, Lobo et al. 2009). Briefly, sixteen SD rats
weighed between 275 and 300g were purchased from Harlan Inc. (Indianapolis, IN). Rats
were randomly assigned to CNTL diet water, HF diet water, CNTL diet SGP or HF diet
SGP groups for two weeks prior to initiation of water or SGP treatment. All animals were
given deionized water ad libitum. HF diet (D12492) containing 60% kcal% fat from lard
and CNTL diet (D06041501P) containing 10% kcal% fat were purchased from Research
Diets Inc. (New Brunswick, NJ). The diet composition is listed in Table 3.1. Body weight
and food intake were monitored every other day throughout the study. According to the
food intake, caloric intake was calculated based on the energy the diets provided. HF
diet provided 5.24 kcal/g pellet and CNTL diet provided 3.85 kcal/g pellet. After two
weeks on CNTL or HF diet, rats were treated with deionized water or SGP by daily
intragastric gavage for ten days. SGP consisted of 150 mg/kg BW of GSE, 62 mg/kg BW
of Concord grape juice and 297 mg/kg BW of trans resveratrol all based on the total
phenolic contents. Total polyphenol contents for GSE is 58% wt/wt, resveratrol is 69%

50
wt/wt and Concord grape juice is 0.23% wt/v analyzed by Folin Ciocalteu assay.
Appropriate amount of SGP was mixed with deionized water to 1.0 mL and delivered to
rats as the first gavage. Residual doses were rinsed with 0.5 mL deionized water and
administered to rats as the second gavage. Rats were gavaged twice a day, 8h apart to
reach the proper dosage.
Table 3.1. Diet composition of HF and CNTL diet.

Ingredient
Protein

Kcal %
HF
20

Kcal %
CNTL
20

Carbohydrate

20

70

Fat

60

10

Total

100

100

Kcal/gm

5.24

3.85

Other Ingredients

kcal

kcal

Casein

800

800

L Cysteine

12

12

Corn Starch

0

1260

Maltodextrin

500

140

Sucrose

275.2

1400

Cellulose

0

0

Soybean oil

225

225

Lard

2205

180

Mineral mix

0

0

Vitamin mix

40

40

Blue Dye

0

0

Total

4057

4057

SGP Pharmacokinetics.
The procedure of the pharmacokinetic study was based on (Ferruzzi, Lobo et al. 2009).
In brief, at the eighth day of SGP treatment, rats were anesthetized by given 3 5% of
isoflurane in the anesthesia chamber and maintained with a mask with 1.5 3%
isoflurane. A handmade polyethylene catheter was implanted into a rat’s jugular vein
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for blood draw. Rats were injected with Buprenex (0.01 0.05mg/kg) before regaining
consciousness to alleviate pain. Catheters were kept patent by flushing with heparinized
saline (100 units/mL) every 12 h. Rats were allowed to rest for 24 h to recover after
surgery. After fasted for 8h, a pharmacokinetic study was initiated and food was offered
again 2 h after SGP treatment. Pharmacokinetics was conducted based on the following
schedule by collecting 400 L of blood at 0 (before gavage), 0.25, 0.5, 1, 2, 4, 6, 8 h post
gavage from the jugular catheter into heparinized tubes. Heperinized blood was
centrifuged at 6500 rpm for 10 min at 4

resulting in 200 L of plasma. Plasma was

acidified with acidified saline (1% ascorbic acid wt/v) in 4:1 ratio, purged with N2 and
stored at 80

until analysis. The day after pharmacokinetics, another dose was

administered and rats were sacrificed 1h post dose. Rats were then perfused with ice
cold saline to remove possible blood contamination. Brain tissues were harvested and
snap frozen in liquid nitrogen.

Polyphenol Metabolites Extraction in Plasma and Brain Tissues.
Monomeric flavan 3 ols, resveratrol and Q metabolites were extracted from plasma
(~100 L) by SPE using 1 cc Waters Oasis HLB cartridges (Milford, MA). Acidified plasma
samples were thawed in room temperature, brought up to 0.5 mL with acidified saline
(0.1% formic acid v/v) and vortex for 5s. SPE cartridges were preconditioned with 1 mL
of ddH2O followed by 1 mL of methanol and samples were loaded onto the cartridges.
The cartridges were then cleaned with 1 mL of 1.5M formic acid (v/v) followed by 1 mL

52
of 5% methanol (v/v). After cleaning, polyphenols in plasma were eluted with 2 mL of
methanol and dried under vacuum at 37

. Dried phenolic extracts were reconstituted

with 0.1% aqueous formic acid (v/v) and 0.1% formic acid in acetonitrile (v/v) in 4:1 ratio.
Reconstituted samples were vortex and sonicated for 10s and analyzed by LC MS/MS.
Brain tissues were weighed and finely diced into pieces and homogenized with ice cold
methanol (9 mL/g tissue) until a homogenate was obtained. Brain homogenates were
centrifuged at 3700 rpm at 4

for 10 mins. Top layer methanol was collected. The

methanol extraction process was repeated again with 6 mL of methanol/g tissue.
Methanol was dried under 37

vacuum. Dried residuals were reconstituted with 1 mL

0.1% aqueous formic acid (v/v) and underwent the same SPE procedure as plasma
described above.
Anthocyanins were extracted using the same Waters Oasis HLB cartridges and the
same procedure except for the use of different solvents. SPE cartridges were
preconditioned with 3 mL of ddH2O followed by 3 mL of methanol and samples were
loaded onto the cartridges. 3 mL of 2% aqueous formic acid (v/v) was used to wash the
cartridges. Anthocyanins were eluted with 2 mL of 2% formic acid in methanol (v/v) and
dried under vacuum at 37 . Dried extracts were resolubilized in 100 L of 2% aqueous
formic acid (v/v) for LC MS/MS analysis. Anthocyanins in brain tissues were extracted
with ice cold methanol followed the same procedure as above and underwent
anthocyanin SPE.
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LC MS Analysis of SGP Material, Plasma and Brain Tissues.
SGP material. SGP containing 61.8 mg resveratrol, 34.0 mg GSE and 0.40 mL Concord
grape juice was analyzed LC MS by Rutgers University. This preparation was adopted
from half of the animal dosage based on a rat weighed ~250 g. HPLC separation was
performed on a Polaris amide C18 column, 250 x 4.6mm, 5um (Varian Inc.). For LC MS
analysis, a Hewlett Packard Agilent 1100 Series LC MS (Agilent Technologies, Waldbronn,
Germany) equipped with autosampler, quaternary pump system, DAD detector,
degasser, MSD trap with an electrospray ion source (ESI), and software for data
processing was HP ChemStation. The identification of anthocyanins, flavonols, phenolic
acids and flavanols were achieved by using the same LC gradient, but with different MS
ionization mode and mobile modifiers. Anthocyanins and flavonols were detected under
positive ion mode with 0.4% TFA (v/v) in water and ACN. Phenolic acids and
flavanols/proanthocyanidins were detected under negative ion mode with 0.1% formic
acid (v/v) in water and ACN. HPLC separation was performed with the mobile phase
containing solvent A (0.4% TFA or 0.1% FA in water) and B (0.4% TFA or 0.1% FA in ACN)
in gradient: 0 20 min, linear gradient from 10 % to 20 % B; 20 30 min, linear gradient
from 20% to 30% B; 30 40 min, isocratic elution at 30% B; 40 50 min, linear gradient
from 30% to 50%; 50 60 min, linear gradient from 50% to 60%. The flow rate was set at
1.0 mL/min. The UV detector was set at 254, 280, 370, 520 nm. The eluent was
monitored by electrospray ion mass spectrometer (ESI MS) scanned from m/z 100 to
1200. ESI was conducted by using a needle voltage of 3.5 KV (positive) and 3.5 KV

54
(negative). High purity nitrogen (99.999%) was used as dry gas at a flow rate of 12 L/min
and capillary temperature was at 350°C. Nitrogen was used as nebulizer at 60 psi, and
Helium as collision gas. For the detection of resveratrol, an isocratic method was used
consisting of 60% solvent A (40 M ammonium acetate in ddH2O) and 40% solvent B
(acetonitrile). The flow rate was 0.5mL/min, and the run length was 20 minutes. The UV
detector was set at 305nm, and MS detection was set under negative mode. The eluent
was monitored by electrospray ion mass spectrometer (ESI MS) scanned from m/z 100
to 600. ESI was conducted by using a needle voltage of 3.5 KV (negative). High purity
nitrogen (99.999%) was used as dry gas at a flow rate of 8 L/min and capillary
temperature was at 350°C. Nitrogen was used as nebulizer at 40 psi, and Helium as
collision gas.

Flavan 3 ol and Q metabolites LC MS Analyses.
Analyses of flavan 3 ol metabolites from plasma was performed on an Agilent 1100
time of flight. Analysis of all brain samples and plasma for Q metabolites and
anthocyanins was performed on an Agilent 6400 Triple Quad equipped with Jetstream
electrospray ionization (ESI) source under multiple reaction monitoring modes (MRM). A
Waters XTerra RP C18 column (2.1 mm x 100 mm, 3.5 m particle size) was used on
both systems. A binary mobile phase system consisted of A: 0.1% aqueous formic acid
(v/v) and B: 0.1% formic acid in acetonitrile (v/v) was used. The column was heated to
30

and the system flow rate was 0.3 mL/min. The binary gradient to elute monomeric
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flaval 3 ols and Q metabolites was described as followed: 10% B at 0 min, 40% B at 5.5
min, 70% B at 7 min, 95% B at 7.5 min and back to 10% B at 8.5 min and continue onto
13.5 min. MS data was obtained under negative polarity. ESI source conditions: gas
temperature was 350 , drying gas flow was 11 l/min, nebulizer was 30 psi, sheath gas
temp was 350 , sheath gas flow was 11 L/min, capillary voltage was 3500V and nozzle
voltage was 1000V.

Anthocyanin Analysis.
A Waters XTerra RP C18 column (2.1 mm x 100 mm, 3.5 m particle size) was used
and heat up to 35

. The binary mobile phases were A: 2% aqueous formic acid (v/v)

and B: 0.1% formic acid in acetonitrile (v/v). The LC gradient is 5% B at 0 min, 10% B at
10 min, 25% B at 30 min, 5% B at 31 min and continue on 5% B to 35 min. MS data was
obtained under positive polarity. MS condition was the same as described above.

Data Analysis.
Data were expressed as mean ± standard error of mean (SEM). Pharmacokinetic
parameters including plasma area under the curve from 0 to 8h (AUC0 8h) was calculated
using the trapezoidal rule and the maximum plasma concentration (Cmax) and the time
at the maximum plasma concentration (Tmax) were obtained from the pharmacokinetic
curves expressed as plasma concentration versus time. Significance among groups on
body weight gain, food intake and energy intake were determined using one way
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ANOVA by SAS 9.3 (Cary, NC) with Tukey’s post hoc test to determine pairewise
differences. The differences between HF SGP and CNTL SGP groups on pharmacokinetic
parameters and brain levels were determined by Student’s test. Significance was
accepted at the level of <0.05.

3.3

Results

SGP Material Profile.
The major flavan 3 ols, flavonols and anthocyanins from SGP were detected by UV at
280, 370 and 520 nm determined by Dr. Jim Simon from Rutgers University.
Quantification of major polyphenols in SGP was shown in Table 3.2
.
Table 3.2. Major polyphenols in SGP.
Polyphenol
Class

Flavonols

Flavan 3 ols

Anthocyanins

Stilbenoids

Polyphenols

Q 3 gluc

Q 3 glucur

C

EC

Mv
gluc

Pt
gluc

Dp
gluc

Pn
gluc

Cy
gluc

Resveratrol

Concentration
(mg/100g)

3.5

5.5

546

649

1.4

1.5

3

trace

2.3

11427

Animal body weight and food intake.
Mean body weight gain was calculated by the difference from the day rats started
respective diet and the day before jugular vein surgery. After surgery, rats tended to
lose weight which might create bias. There was no significant difference among groups
on mean body weight gain, however, there was a slightly decrease in HF water and HF
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SGP groups compared to rats in CNTL diet groups (Figure 3.1.). The decrease in body
weight in both HF groups was consistent with the decreased food intake (Figure 3.1.).
Despite the decrease in body weight change and food intake, the energy intake for both
HF groups was positively increases compared to the CNTL diet groups, however, the
trend showed no significance (Figure 3.1.). Our results concluded that repeated dose of
SGP did not influence body weigh gain, food intake and energy intake regardless the fat
content in diets.
(A)

Mean Body Weight Gain

Mean body weight gain (g)

150

100

50

0
CNTL water HF water1 CNTL SGP HF SGP

Mean Food Intake

50

Mean food intake (g/day/rat)

(C)

Mean energy intake (kcal/day/rat)

(B)

40
30
20
10
0
CNTL water HF water 1 CNTL SGP HF SGP

Mean Energy Intake
100
80
60
40
20
0
1

CNTL water HF water CNTL SGP HF SGP

Figure 3.1. Mean body weight change, mean food intake and mean energy intake of the
rats.
Data represented as mean ± SEM. (n=4/group).
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SGP Bioavailability in SD Rat Plasma.
Flavan 3 ol. Flavan 3 ols, C and EC, from GSE in SGP were metabolized to produce
catechin 5 glucuronide (C 5 glucur), epicatechin 5 glucuronide (EC 5 glucur), 3’ O
methylcatechin 5 glucuronide (3’OMeC 5 glucur)and 3’ O methylepicatechin 5
glucuronide (3’OMeEC 5 glucur) found in plasma and brain tissues. The eight hour
pharmacokinetic profiles were depicted in Figure 3.2. All four flavan 3 ol metabolites
reached Tmax within 1 to 2 hour after SGP treatment regardless the background diet
condition (Table 3.3.). Rats on CNTL diet showed no significant differences on Cmax and
AUC0 8h on C 5 glucur, 3’MeOC 5 glucur and 3’MeOEC 5 glucur compared to rats fed on
HF diet suggesting that plasma bioavailability was not affected by background diet fat
content. One exception was EC 5 glucur in which rats fed on CNTL diet had significantly
lower Cmax (p=0.02) and AUC0 8h (p=0.03) compared to rats fed on HF diet.
Quercetin. Quercetin 3 glucuronide (Q 3 glucur) and methylquercetin glucuronide
(MeO Q glucur) were detected in plasma from rats repeatedly treated with SGP for 10
days. The eight hour pharmacokinetic behavior was shown in Figure 3.3. MeO Q 3
glucur reached Tmax at 30 min after SGP treatment for HF and CNTL diet groups. Q 3
glucur peaked between 15 min and 30 min for HF and CNTL diet groups after SGP
treatment. Plasma AUC0 8h was determined at nano molar range. Rats showed similar
AUC0 8h and Cmax regardless the fat content in diets on Q 3 glucur and MeO Q glucur
(Table. 3.4.).
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Resveratrol. Resveratrol 3 glucuronide (Res 3 glucur) was the main metabolite detected
in plasma and brain tissues from resveratrol fraction of SGP. Eight hour pharmacokinetic
response of Res 3 glucur are depicted in Figure 3.3. Rats on CNTL diet group showed
significantly higher plasma Cmax (p=0.02) compared to the rats on HF diet group
suggesting that HF diet might hinder Res 3 glucur bioavailability. However, AUC0 8h was
not significantly different between CNTL and HF groups (Table 3.5.).
Anthocyanins. Five major anthocyanins including Mv, Cy, Dp, Pn and Pt glucoside were
detected in plasma and brain tissues. There were no datectable anthocyanidin
glucuronides found in plasma. Pharmacokinetic curves of anthocyanins are shown in
Figure 3.4. All anthocyanins demonstrated Tmax at 0.25h regardless of fat content in
diets. This is consistent with other reports that demonstrated the rapid plasma increase
in the gastric environment is indicative that stomach is a major absorption site for
anthocyanins (Passamonti, Vrhovsek et al. 2003; Talavera, Felgines et al. 2003). There
were no significant differences found in Cmax and AUC0 8h on anthocyanins between
CNTL and HF diet groups (Table 3.6.). Although Cy 3 glucoside was the second highest
abundant anthocyanin components in the Concord grape juice, it showed the highest
Cmax (9.61 and 8.97 nmol/L plasma for CNTL and HF diet group) compared to the other
anthocyanins (average of 4.00 nmol/L plasma). Overall, fat content in the background
diet seemed to have no effects on plasma bioavailability of anthocyanins (Table 3.6.).
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Figure 3.2. Plasma pharmacokinetic responses of flavan 3 ol metabolites.
Data represented as mean ± SEM (n=3/group).

Table 3.3. Pharmacokinetic parameters of flavan 3 ol metabolites.
Diet

Compound

AUC (nmol/L h)

C max (nmol/L)

Tmax (h)

CNTL

C 5 glucur

7888.9 186.5

2458.4 263.4

1.7 0.3

9192.9 747.5

3660.6 783.4

2.0 0.0

9122.2 303.9

2791.4

188.7

1.7

0.3

5058.4

588.6*

2.0

0.0

HF
CNTL

EC 5 glucur

HF
CNTL

14654.0
3’OMeC 5 glucur

HF
CNTL
HF

3’OMeEC 5 glucur

1571.7*

12566.0 557.4

2820.5 67.8

2.0 0.0

12545.9 772.0

2964.8 54.1

2.0 0.0

18463.3 472.7

4203.6 128.5

2.0

0.0

4430.3

2.0

0.0

18345.4

Data represented as mean ± SEM (n=3/group).

1540.4

71.0

8
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Figure 3.3. Plasma pharmacokinetic responses of quercetin and resveratrol metabolites.
Data represented as mean ± SEM (n=3 4/group).

Table 3.4. Pharmacokinetic parameters of quercetin metabolites.
Diet

Compound

AUC (nmol/L h)

C max (nmol/L)

Tmax (h)

CNTL

MeQ Q glucur

410.1 43.9

78.8 8.8

0.5 0.2

370.8 14.8

95.7 9.6

0.6 0.2

385.4 72.2

118.6 41.5

0.3 0.0

467.4 115.0

208.1 90.3

0.3 0.1

HF
CNTL
HF

Q 3 glucur

Data represented as mean ± SEM (n=4/group).
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Table 3.5. Pharmacokinetic parameters of resveratrol metabolite.
Diet

Compound

AUC (µmol/L h)

C max ( mol/L)

Tmax (h)

CNTL

Res glucur

456.4 76.0

78.5 3.2

1.0 0.5

242.3 32.0

58.2 4.4*

0.5 0.0

HF

Data represented as mean ± SEM (n=4/group).

Mv glucoside

Pt glucoside

14

14

CNTL SGP

12

12

HF SGP

10

10

8

8

6

6

4

4

2

2

0

0
0

1

2

nmol/L plasma
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3

4

5

6

7

8
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0

1

2
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10

8

8

6
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2

2

0
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8
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0
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Figure 3.4. Plasma pharmacokinetic responses of major anthocyanins.
Data represented as mean ± SEM (n=4/group).
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Table 3.6. Pharmacokinetic parameters of anthocyanins.
Diet

Compound

AUC (nmol/L h)

C max (nmol/L)

Tmax (h)

CNTL

Mv glucoside

15.9 0.4

4.2 0.4

0.3 0.0

17.3 0.5

3.7 0.1

0.3 0.0

19.8 4.1

3.1 0.1

0.3 0.0

16.4 0.3

3.3 0.2

0.3 0.0

16.8 0.2

4.2 0.1

0.3 0.0

16.9 0.3

4.0 0.3

0.3 0.0

17.4 0.5

3.9 0.2

0.3 0.0

18.3 0.8

3.6 0.3

0.3 0.0

10.3 1.5

9.6 0.9

0.3 0.0

14.1 1.0

9.0 0.5

0.3 0.0

HF
CNTL

Pt glucoside

HF
CNTL

Dp glucoside

HF
CNTL

Pn glucoside

HF
CNTL
HF

Cy glucoside

Data represented as mean ± SEM (n=4/group).

SGP Polyphenol Metabolites in SD Brain Tissue.
Flavan 3 ols. Brain concentration of flavan 3 ol metabolites were determined to be at
pico molar per gram of tissue range regardless the fat content in the background diet.
Although rats fed on HF diet seemed to have slightly higher brain deposition levels on C
5 glucur, EC 5 glucur, 3’OMeC 5 glucur and 3’OMeEC 5 glucur, none of these effects
reached the level of statistical significance compared to the CNTL diet group (Figure 3.5.).
There were no flavan 3 ol metabolites detected in the water treated groups.
Quercetin. Brain concentration was detected at pM level for quercetin metabolites. The
brain deposition levels for Q 3 glucur and MeO Q glucur were not significantly different
between CNTL and HF diet group (Figure 3.6.).
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Resveratrol. Brain deposition level was determined to be at nM level for Res 3 glucur
which compares to its plasma level at micro molar per gram of tissue. There was no
significant difference found between CNTL and HF diet groups (Figure 3.6.).
Anthocyanins. Brain concentrations were determined to be at pico molar per gram of
tissue range for all major anthocyanins in SGP. Like other polyphenol in SGP, there was
no significant difference detected in brain on anthocyanins between CNTL and HF diet
groups (Figure 3.7.).
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Figure 3.5. Brain responses of flavan 3 ols.
Data represented as mean ± SEM (n=3/group).
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Figure 3.6. Brain responses of quercetin and reveratrol metabolites.
Data represented as mean ± SEM (n=3 4/group).
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Figure 3.7. Brain responses of anthocyanins.
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3.4

Discussion

Polyphenol metabolic profiles. We have previously demonstrated the bioavailability
studies on a SD rat model gavaged individually with GSE, wine and resveratrol
(Marambaud, Zhao et al. 2005; Ferruzzi, Lobo et al. 2009; Ho, Chen et al. 2009). The
major polyphenols in these extracts are subjected to similar xenobiotic metabolism and
are suspected to be the substrates for similar efflux proteins like p glycoprotein,
multidrug resistance associated proteins and breast cancer resistance protein that limit
their overall bioavailability (Monagas, Urpi Sarda et al. 2010). It is reasonable to
hypothesize that circulating and tissue profile of polyphenol metabolites might be
modulated when treated simultaneously compared to individually. Our data suggested
that similar metabolic profile was found when rats were gavaged with SGP versus
individual polyphenol extract (Table 3.7.). Four flavan 3 ol metabolites including C 5
glucur, EC 5 glucur, 3’OMeC glucur and 3’OMeEC glucur were derived from C and EC
which are the dominant components in GSE. Grape juice, which has similar composition
to red wine, is enriched in quercetin 3 glucuronide and quercetin 3 glucoside which can
be transformed to form Q glucur and MeO Q glucur. Resveratrol is confirmed to be
metabolized to Res glucur regardless treated in combination with others or in individual
form. These data confirm that when ingested in combination, polyphenol metabolic
profile is not likely altered to a large extent. This supports the notion that combination
treatment of polyphenols can be leveraged for future studies focused on AD prevention.

68
Table 3.7. Comparison of major polyphenol metabolites detected in Sprague Dawley
rats when treated individually or simultaneously.
SD rats

Individual polyphenol rich product
GSE

Flavan 3 ol

1

2

SGP

Concord grape juice

Resveratrol

N/A

N/A

C 5 glucur
EC 5 glucur

4

3

C 5 glucur
EC 5 glucur

3’OMeC 5 glucur

3’OMeC 5 glucur

3’OMeEC 5 glucur

3’OMeEC 5 glucur
Q 3 glucur

Flavonol

N/A

N/A
MeO Q glucur

Q 3 glucur
MeO Q glucur

Mv glucoside
Mv glucoside
Pt glucoside

Pt glucoside
Anthocyanin

Resveratrol

N/A

N/A

Dp glucoside

N/A

Dp glucoside

Pn glucoside

Pn glucoside

Cy glucoside

Cy glucoside

N/A

Res 3 glucur

Res 3 glucur

1 (Wang, Ferruzzi et al. 2012)
2 in preparation
3 (Vingtdeux, Giliberto et al. 2010)

HF intervention and body weight change. In order to investigate how background
dietary fat levels influences polyphenol absorption, SD rats were fed on 60% kcal% fat
diet for 2 weeks prior to SGP gavage to induce condition the animals. However, our data
did not show significant difference on major SGP polyphenol bioavailability between
CNTL and HF background diet groups on brain levels as well as key PK parameters
including Cmax and AUC0 8h. The exception to this was for EC 5 glucur and Res 3 glucur. It
has been reported that SD rats respond to HF diet differently depending on their genetic
background and also the training of their responsiveness to signaling and cues (Rada,
Bocarsly et al. 2010). It has been suggested that within the SD rat species, they can be
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grouping into obesity prone and obesity resistance (Levin and Keesey 1998;
Dourmashkin, Chang et al. 2006). Another study showed that SD rats fed on 3 month of
HF diet did not develop obesity or any other metabolic changes such as insulin
resistance or glucose intolerance(Stark, Timar et al. 2000). In the present study, rats
were not particularly trained to respond to cues associated with specific diet nor being
characterized as obesity prone or obesity resistance and therefore, may be adaptive to
HF diet to maintain body weight. The adaptation to HF may have manifested in lower
food intake observed in the HF diet group compared to that in the CNTL diet group
(Figure 3.1.) which suggested that SD rats might adapt to HF load in diet.
Overall, the unchanged body weight in SD rats well represented model of transient HF
consumption in physiological healthy individuals. Furthermore, our data ruled out the
potential confounding factor that the obese state might also influence polyphenol
bioavailability (addressed in a different model in Chapter IV). There were reports
showing that people lose weight when given HF nuts as snacks (Willette, Xu et al.). The
possible mechanism was proposed by Mattes et al. (Mattes and Dreher ; Mattes, Kris
Etherton et al. 2008) that the fats were energy dense and highly satiable and therefore
might decrease food intake. This was consistent with our data showing that HF diet
groups showed a trend of decreased body weight change and food intake compared to
the CNTL diet groups.
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Difference in polyphenol bioavailability responded to HF intervention. In general, HF
diet did not significantly influence polyphenol bioavailability, metabolism or brain
distribution of compounds derived from SGP. With the exception of EC 5 glucur and
Res 3 glucur, HF background diets seemed to result in improved plasma bioavailability
of EC 5 glucur indicating by significantly higher AUC0 8h and Cmax compared to CNTL
(Table 3.2. and 3.3.). Our data suggested that fat content might help EC 5 glucur
absorption. This is consistent with the study which showed that the higher fat content in
cocoa liquor had better bioaccessibility compared to the lower fat cocoa powder due to
a better micellarization of monomeric and dimeric flavan 3 ols (Ortega, Reguant et al.
2009). Interestingly, acute exposure to fat has been shown to improve bioavailability of
other polyphenols including quercetin in humans (Guo, Mah et al. 2013). While similar
effects may be possible in the current study, SGP dose treatments were not given to SD
rats along with HF diet. Animals were in fact dosed after an overnight fast. Therefore,
the mechanism behind this improvement in bioavailability for EC glucur is not clear.
More studies are needed to further explain such observation. On the other hand, Cmax of
Res 5 glucur was significantly higher in the CNTL diet group. It is suspected that
excessive fat content might influence the expression of key metabolizing enzymes
directly involved in polyphenol metabolism (Kim and Novak 2007). However, the
mechanism should be further investigated.
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Difference in brain penetration of polyphenol metabolites responded to HF
intervention. Similar to plasma responses, effects of fat content in the background diet
on brain concentrations of all four flavan 3 ol metabolites are limited. No significant
differences were found on brain levels of quercetin, resveratrol metabolites and
anthocyanins between HF and CNTL diets. Since the mixture of SGP contained different
dosage of major polyphenol classes, we normalized the average Cmax, AUC and brain
concentration of key polyphenol metabolites by SGP dose in proportion to their
concentration in the mixture (Table 3.8.). After the normalization process by SGP dose,
the four major flavan 3 ol metabolites showed the highest brain levels at 200 nM/mg
tissue compared to other metabolites. Interestingly, res 3 glucur showed a brain
concentration at 13 nM/mg tissue even at a high dose of 56mg. These data suggested
that flavan 3 ol metabolites are preferably selected to access brain tissues compared to
other SGP polyphenols. This is indicative that flavan 3 ol metabolites are potent
bioactive compounds with high brain targeting ability which can be recommended for
further studies on AD prevention.
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Table 3.8. Normalized Cmax, AUC and brain levels by SGP dose.
SD rats on CNTL diet
Metabolite
C 5 glucur
EC 5 glucur
3'OMeC 5 glucur
3'OMeEC 5 glucur

Normalized by Dose
Concentration in
SGP (mg/g)
Dose (mg) C max (µmol/L) AUC (µmol/L*h) Brain (pmol/g) C max ( M/mg) AUC (µM*h/mg) Brain (nM/mg)
5.600
2.776
2.460
7.890
485.790
0.886
2.842
174.966
6.490
3.218
2.790
9.120
637.220
0.867
2.834
198.033
5.600
2.776
2.820
12.570
664.290
1.016
4.527
239.256
6.490
3.218
4.200
18.460
853.830
1.305
5.737
265.351

Q 3 glucur
MeO Q glucur

0.090
0.090

0.045
0.045

0.119
0.079

0.385
0.410

2.410
0.690

2.658
1.766

8.636
9.191

54.009
15.463

Mv glucoside
Pt glucoside
Dp glucoside
Pn glucoside
Cy glucoside

0.014
0.015
0.030
0.010
0.023

0.007
0.007
0.015
0.005
0.011

0.004
0.003
0.004
0.004
0.010

0.016
0.020
0.017
0.017
0.010

0.170
0.100
0.070
0.120
0.070

0.602
0.418
0.282
0.785
0.843

2.294
2.668
1.129
3.507
0.901

24.491
13.446
4.706
24.203
6.139

Res 3 glucur

114.000

56.521

78.530

456.440

746.570

1.389

8.076

13.209

3.5

Conclusions

The goal of this study was to investigate the effect of transient HF consumption and the
HF matrix on grape polyphenol bioavailability and brain deposition level. While
bioavailability of flavonoids can be affected by macronutrient content (Ferruzzi 2010;
Bandyopadhyay, Ghosh et al. 2012), few studies have investigated the direct effect of
dietary fat content on polyphenol bioavailability. This study was the first to our
knowledge that tested the bioavailability on previously proven effective grape
polyphenols, GSE, grape juice and resveratrol, on SD rats fed on CNTL or HF diet for 3
weeks. We have found that different background diets with high or low fat contents
showed limited effect on plasma bioavailability of individual flavan 3 ol metabolites
with the exception of EC 5 glucur and Res 3 glucur. Further brain levels of individual
metabolites of SGP did not differ regardless of the background diet. In conclusion, our
data suggested that the transient high fat ingestion for up to 3 weeks on physiologically
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healthy rats did not significantly influence the overall plasma bioavailability and brain
levels of polyphenols from an SGP preparation.
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CHAPTER 4. INFLUENCE OF DIABETES ON PLASMA PHARMACOKINETICS AND BRAIN
BIOAVAILABILITY OF GRAPE POLYPHENOLS IN THE ZUCKER DIABETIC FATTY RAT
MODEL

Abstract
Grape polyphenols are believed to be biologically active agents capable of modulating
Alzheimer’s disease (AD) risk factors. Diabetes mellitus is a known risk factor for
development of AD. To investigate the effect of the diabetic condition on bioavailability
and brain distribution of grape derived flavan 3 ols, flavonols, and anthocyanins, Zucker
diabetic fatty (ZDF) rats and their lean controls (LN) were dosed orally with a
combination of grape polyphenols termed Standardized Grape Polyphenol (SGP) which
consisted of grape seed extract (GSE), Concord grape juice and resveratrol (Res). Each
component had previously been found effective in prevention of AD in a mouse model
(Wang, Ho et al. 2008; Vingtdeux, Giliberto et al. 2010). Eight hour plasma
pharmacokinetics was conducted after a 10 day oral gavage treatment of SGP or water.
LC MS/MS analysis confirmed metabolites of catechin (C) and epicatechin (EC) as C/EC
5 glucuronide (C/EC 5 glucur) and 3’ methyl C/EC 5 glucuronide (3’ OMeC/EC 5 glucur).
The main metabolites of quercetin (Q) present in plasma and brains were determined to
be Q 3 glucuronide (Q 3 glucur) and methyl Q glucuronide (MeO Q glucur). Res 3
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glucuronide (Res 3 glucur) was the main metabolite identified derived from resveratrol
in plasma and brain extracts.
ZDF rats exhibited significantly diminished Cmax for C/EC 5 glucur (p=0.01 and
p=0.008), 3’ OMeC/EC 5 glucur (p<0.0001), Q 3 glucur (p=0.01), MeO Q glucur (p=0.006)
and Res 3 glucur (p=0.003). Bioavailability defined as plasma area under the curve (AUC)
was found to be significantly lower in ZDF rats for 3’ OMeC 5 glucur (25.09±13.47 vs.
108.09±6.65 mol/L*h, p<0.0001), 3’ OMeEC 5 glucur (22.95±12.40 vs. 110.26±5.94
mol/L*h, p<0.0001), Res 3 glucur (180.78±20.54 vs. 328.85±40.53 mol/L*h, p=0.006),
Q 3 glucur (28.63±2.73 vs. 50.72±7.26 nmol/L*h, p=0.02) and MeO Q glucur
(71.86±3.21 vs. 123.03±19.85 nmol/L*h, p=0.03) than the LN rats. Additionally, ZDF rats
showed significantly lower levels in all stilbene, flavanol and flavan 3 ol metabolites
found in brain tissues. There was no significant differences in anthocyanins in plasma
between ZDF and LN, and no anthocyanins were detectable in brain extracts. ZDF rats
showed significantly higher urinary excretion for all polyphenols from SGP. These data
suggested that the diabetes negatively impact absorption and brain distribution of
polyphenol metabolites in vivo, potentially due, in part, to higher urinary clearance of
absorbed metabolites. This study suggests that dosages required to reach therapeutic
efficacy may need to be adjusted based on the presence and/or severity of diabetes.
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4.1

Introduction

AD is an age related neurodegenerative disease projected to affect more than 5
million Americans by the year 2050 (Hebert, Scherr et al. 2003) with an estimated cost
of $148 billion (Alzheimer's 2009). Despite its severity and economic burden, there is
currently no cure. Diabetes mellitus is a condition defined by hyperglycemia which leads
to high risks of microvascular damage including retinopathy, nephropathy and
neuropathy (WHO 2006). Diabetes affected 25.8 million people in the United States in
2010 which accounted for 8.3% of the U.S. population (CDC 2011). Like AD, diabetes
poses a huge economic burden on the society with $174 billion dollars medical costs
estimated in 2007 (CDC 2011).
Sedentary life style and high fat consumption are believed to contribute to the
development of metabolic syndrome which may eventually progress to diabetes. In a 27
year longitudinal population based study, obesity and body mass index has been
strongly associated with onset of dementia and AD (Whitmer, Gunderson et al. 2005).
The same group also highlighted that body mass index was a risk factor for AD (Whitmer
2007; Whitmer, Gunderson et al. 2007). Disturbances in insulin signaling in diabetes
have been suggested to be a contributing factor for AD development and progression (Li
and Holscher 2007). The Rotterdam study suggested that insulin resistance increased
the chances of progression to AD at a 3 year follow up by 40% (Schrijvers, Witteman et
al.). In a recently published four year longitudinal study, researchers found that insulin
resistance in a late middle aged cohort is positively associated with brain atrophy in the
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regions that are affected by early AD. Their results suggested that higher insulin
resistance predicted medial temporal lobe atrophy associated with cognitive deficits
(Willette, Xu et al.). Considering the link between the diabetic state and
neurodegenerative process, diabetic and metabolic syndrome patients are likely targets
for AD preventive treatments.
Individual grape derived products including purple grape juice, red wine, grape skin
and seed extracts have been shown to have biological activities consistent with the
prevention or amelioration of diabetes and AD in rodent models (Marambaud, Zhao et
al. 2005; Wang, Ho et al. 2006; Wang, Ho et al. 2008; Chis, Ungureanu et al. 2009; Wang,
Thomas et al. 2009; Drel and Sybirna 2012; Huang, Tsai et al. 2012). These polyphenol
rich products provide distinct polyphenol profiles including flavan 3 ols, flavonols, and
stibenoids such as resveratrol. While present in the extract, conjugated metabolites of
these parent polyphenol forms have been identified in circulation and in brain tissue
(Ferruzzi, Lobo et al. 2009; Vingtdeux, Giliberto et al. 2010; Ho, Ferruzzi et al. 2012;
Wang, Ferruzzi et al. 2012). These metabolites including both methylated and
glucuronidated conjugates have demonstrated the ability to target distinct molecular
mechanisms related to AD (Vingtdeux, Giliberto et al. 2010; Ho, Ferruzzi et al. 2012;
Wang, Ferruzzi et al. 2012). For example, 3’ O methyl epicatechin 5 glucuronide, a
metabolite derived from flavan 3 ol in grape seed extract have been shown to restore
synaptic plasticity in the brain of AD mice (Wang, Ferruzzi et al. 2012). Resveratrol has
been shown to activated AMPK pathway which in term rediced cerebral A levels in AD
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mice (Vingtdeux, Giliberto et al. 2010). These observations stimulate interests in
devising combination strategies favoring simultaneous delivery of all bioactive brain
targeting polyphenol metabolites to brain tissues. Interestingly, impaired insulin
signaling, a major defect of type II diabetes is believed to alter expression of key
metabolizing enzymes responsible for generation of bioactive polyphenol metabolite
forms including UDP glucuronosyltransferase and sulfotransferases (Kim and Novak
2007). Additionally, the diabetic condition may alter gastrointestinal mobility and
endogenous hormone secretion in diabetes that can, in turn, impact polyphenol
absorption and metabolism rate (Samsom, Vermeijden et al. 2003). Diabetes has been
shown to alter the function of enteric nervous system and the secretion and sensitivity
of many key hormones (insulin, glucagon and growth hormone) leading to modifications
in xenobiotic metabolizing system (Chandrasekharan and Srinivasan 2007).
Another complication caused by diabetes is osmotic dieresis and electrolyte
imbalance resulting from hyperglycemia. Osmotic dieresis results in urinary loss of water
and electrolytes and if prolonged can progress to kidney failure (Oh, Joo et al. 2007).
Polyphenols undergoing xenobiotic mechanism are rapidly excreted through urinary
routes. Considering the excessive urinary loss in diabetic animals, the potential impact
to circulating polyphenol metabolites and ultimate delivery to brain tissues may be
significant. Therefore, while the diabetic condition may be a risk factor for AD onset and
progression, it may also require alteration of therapeutic or preventive strategies due to
altered polyphenol bioavailability.
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In order to better understand the impact of the diabetic condition on polyphenol
bioavailability and metabolism, a study examining the pharmacokinetic behavior and
brain deposition of grape derived polyphenol metabolites from SGP mixture of Concord
grape juice, GSE and resveratrol was assessed in both lean and obese ZDF rats.

4.2

Materials and Method

Chemicals and Materials.
(+) C, ( ) EC and Q 3 glucur authentic standards were purchased from Sigma Aldrich
(St. Louis, MO). All extraction and liquid chromatography solvents were HPLC certified
and were obtained from J.T. Baker (Phillipsburg, NJ). GSE MegaNatural® AZ powder was
provided by Polyphenolics (Madera, CA). 100% Concord grape juice (Welch’s) was
loaded onto C18 Solid Phase extraction cartridges (1 c.c.) and washed with ddH2O (0.01%
HCl) to remove sugar. Polyphenols were then eluted with MeOH (0.01% HCl). MeOH was
then removed under vacuum and the resulting concentrate was kept frozen until use.
Resveratrol, Res 3 glucur, malvidin (Mv) 3 glucoside chloride and cyanidin (Cy) 3
glucoside chloride were purchased from ChromaDex (Irvine, CA).

SGP Material Analysis.
Major polyphenol contents in SGP were determined by Rutgers University with the
method described in Chapter 3.
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Animals.
All animal studies were approved by the Purdue University Animal Care and Use
Committee. Twelve 10 week old male ZDF rats and twelve 10 week old male LN rats
were obtained from Charles Rivers Labs (Wilmington, MA). Rats were placed on AIN
93M polyphenol free diet using corn oil replacing soybean oil (Dyets, Bethleham, PA)
with water ad libitum until 13 weeks of age. Diabetes was at an advanced stage in the
ZDF rats at 13 weeks of age. Blood glucose after an 8 h fast was measured by
AlphaTRAK® glucose meter from Abbott Laboratories (32004 02, Abbott Park, IL) the day
before SGP treatment and on the pharmacokinetics day. Blood glucose level higher than
250 mg/dL is considered to be hyperglycemia. Body weight and food intake were
monitored every other day throughout the study.

SGP Pharmacokinetics.
The animal study design was modified from Ferruzzi et al. (Ferruzzi, Lobo et al. 2009)
with minor changes. In brief, 13 weeks old rats were randomly assigned to ZDF control
(CRTL) (n=4), ZDF SGP (n=8), LN CRTL (n=4) and LN SGP (n=8). Rats were placed in
metabolic cages for urine collection and were dosed daily for 10 days with SGP at a dose
of 150 mg/kg BW of GSE, 100 mg/kg BW of Concord grape juice and 297 mg/kg BW of
trans resveratrol (based on total polyphenolic content shown in Table 4.1.). Rats in the
CNTL groups received water. After SGP treatment on the eighth day, rats were
anesthetized with 3 5% of isoflurane and a polyethylene catheter was surgically

81
implanted into the jugular vein for blood sampling. Rats were injected with Buprenex
(0.05 mg/kg) before regaining consciousness to alleviate pain. Catheters were kept
patent by flushing with ~0.3 mL of heparinized saline (100 units/mL) every 12 h. Rats
were allowed to Rest for 24 h to recover after surgery.
Pharmacokinetics was initiated on the tenth day after 8h of fast and food was
returned 2 h after SGP dosage. DI water was added to SGP to a final volume of 1.0 mL.
Residual doses were rinsed with 0.5 mL DI water and administered to rats as the second
gavage. Rats were gavaged twice a day, 8 h apart with half the daily dosage. 12h urine
samples were collected daily via metabolic cages right after daily SGP treatment.
Table 4.1. Total polyphenolic content of Concord grape juice, GSE and resveratrol.

Total Polyphenolic Content

Grape Juice

GSE

wt/wt %

8.8

94

Resveratrol
98

Pharmacokinetic studies were conducted on the 10th day of SGP treatment by
collecting 400 L of heparinized blood at 0, 0.25, 0.5, 1, 2, 4, 6, 8 h post gavage from the
jugular catheter. Heperinized blood was centrifuged at 6500 rpm for 10 min at 4
Resulting in 200 L of plasma. Plasma was acidified with acidified saline (1% ascorbic
acid wt/v) in 4:1 ratio, purged with nitrogen and stored at 80

until analysis. The day

after pharmacokinetics, another dose was administered and rats were sacrificed 1 h
post dose. Rats were then perfused with ice cold saline to remove residual blood from
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tissues. Brain tissues were harvested following perfusion and snap frozen in liquid
nitrogen.

Polyphenol Metabolites Extraction in Plasma, Urine and Brain Tissues.
C/EC, Q, Res metabolites and anthocyanins were extracted from plasma, urine and
brain homogenates by solid phase extraction (SPE) using 1 mL Waters Oasis HLB
cartridges (Milford, MA). The protocol was previously described by Ho et al. (Ho,
Ferruzzi et al. 2012). In brief, acidified plasma, urine and methanolic brain extracts were
loaded onto preconditioned SPE cartridges. The cartridges were washed with 1 mL of
1.5M formic acid (v/v) followed by 1 mL of 5% aqueous methanol (v/v) for C/EC, Q, Res
metabolites, 2 mL of 2% formic acid (v/v) for anthocyanins. C/EC, Q, Res metabolites
were eluted with 2 mL of 0.1% formic acid/methanol (v/v) and anthocyanins were with 2%
formic acid/methanol (v/v). Eluents were dried under vacuum at 37

. Dried extracts

were reconstituted with LC mobile phases for immediate analysis. Plasma from two rats
was combined as one sample to undergo anthocyanin SPE due to their low
concentration in these tissues and fluids.

Polyphenol Analysis of Plasma, urine and Brain Tissues by LC MS or LC MS/MS.
Analyses of C/EC, Q, Res metabolites was performed on an Agilent 6400 Triple Quad
LC/MS equipped with an electron spray ionization (ESI) source under multiple reaction
monitoring modes (MRM). The method was previously described by Ho et al. (Ho,
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Ferruzzi et al. 2012). Briefly, a Waters XTerra RP C18 column (2.1 mm x 100 mm, 3.5 m
particle size) was employed for all analyses. For C/EC, Q and Res, binary mobile phases
were A: 0.1% aqueous formic acid (v/v) and B: 0.1% formic acid in acetonitrile (v/v). The
column was heated to 30

and the system flow rate was 0.3 mL/min. The binary

gradient to elute all polyphenol metabolites was: 10% B at 0 min, 40% B at 10 min, 95%
B at 11 min and back to 10% B at 12 min to 18 min. Fragmentor voltage was set at 135V
and collision energy was 17eV for all compounds. ESI source conditions were as follows:
gas temperature was 350 , drying gas flow was 11 l/min, nebulizer was 30 psi, sheath
gas temp was 350 , sheath gas flow was 11 L/min, capillary voltage was 3500V and
nozzle voltage was 1000V. For anthocyanins, the binary mobile phases were A: 2%
aqueous formic acid (v/v) and B: 0.1% formic acid in acetonitrile (v/v) and the column
was heated up to 35 . The gradient used was: 5% B at 0 min, 10% B at 10 min, 25% B at
30 min, 5% B at 31 min and continue on 5% B to 35 min. ESI source condition setting
was the same as described above.
Flavan 3 ols and resveratrol metabolites in urine samples were analyzed by Agilent
1100 LC time of flight equipped with ESI source. LC conditions were the same as
described above as used in LC MS/MS. MS conditions: gas temperature was 350 ,
drying gas flow was 11 l/min, nebulizer was 30 psi, capillary voltage was 3500V, skimmer
was 60V, fragmentor was 135V and the mass range was 100 1000 m/z. Quercetin
metabolites and anthocyanins were analyzed by triple quadrupole as described above.
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Data Analysis.
Quantification of C/EC, RES and Q metabolites was by multi level response curves
generated from authentic standards of C, EC, Res 3 glucur and Q 3 glucur, respectively.
Quantification of Cy 3 glucoside was calculated from a calibration curve constructed
with authentic standard while other anthocyanins were based on Mv 3 glucoside. All
data are presented as mean ± standard error of the mean (SEM). Pharmacokinetic
parameters including: 1) area under the plasma concentration versus time (AUC0 8h)
were calculated using the linear trapezoidal rule, 2) the maximum plasma
concentrations (Cmax) and, 3) the time at which the maximum concentration (Tmax) were
determined directly from the pharmacokinetic curves of plasma concentration versus
time. Statistical analyses were performed using SAS 9.3 statistical analysis program (Cary,
NC). Group differences of average body weight gain, average food intake and the
difference of fasting blood glucose before and after treatment were determined by one
way ANOVA with Tukey’s post hoc test. Differences between ZDF and LN on
pharmacokinetic parameters, urine concentration and brain concentrations were
analyzed by Student’s t test. The significance was accepted at the level of <0.05.

4.3

Results

Body Weight, Food Intake and Fasting Blood Glucose
Body weight and food intake of all groups were measured every other day (Figure
4.1.). Body weight gain was defined by the body weight difference between the first day
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of treatment and the day of jugular surgery. One of the ZDF CNTL rats lost ~51g of body
weight during the course of water treatment resulting in negative average body weight
gain. This might be due to the severity of diabetes complication progressed as the study
went on. In general, treatment of SGP did not significantly alter body weight gain in
either ZDF or LN rats. SGP also did not have significant effects on average food intake on
LN or ZDF rats. Fasting blood glucose was measured before and after 10 days of SGP
treatment. LN SGP rats had average fasting blood glucose of 107.38 ± 2.07 mg/dL before
SGP treatment and 111.57 ± 2.82 mg/dL after 10 days of SGP treatment. ZDF SGP rats,
on the other hand, had average fasting glucose level of 234.38 ± 16.22 mg/dL prior to
SGP and 300.17 ± 40.89 mg/dL after 10 days of SGP treatment. LN CNTL rats had fasting
blood glucose of 114.25 ± 1.65 before and 116.75 ± 1.65 mg/dL after 10 days of water
treatment. ZDF CNTL rats had fasting blood glucose at 262.50 ± 30.64 before and 346.25
± 19.98 mg/dL after water treatment. The difference of fasting blood glucose before and
after treatment was not significantly different in either diabetic or lean groups
suggesting that 10 day of SGP treatment did not significantly influence fasting blood
glucose level.
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Figure 4.1. Average body weight gain and average food intake of rats.
Data was represented as mean ± SEM (n=4/CNTL group and n=8/SGP group).
Different letter indicates significance among groups.

Characterization of Major Polyphenols in Plasma and Brain Tissues
Four major flavan 3 ol metabolites, C 5 glucur, EC 5 glucur, 3’ OMeC 5 glucur, and 3’
OMeEC 5 glucur were detected in plasma and brain tissues from rats treated with SGP
(Figure 4.2.). Res 3 glucur was the main metabolite from resveratrol found in plasma
and brain tissues (Figure 4.2.). Chemical structures of major SGP polyphenols and
metabolites are shown in Figure 4.3. Major Q metabolites were Q 3 glucur and MeO Q
glucur (structures shown in Figure 4.3.) and representative chromatograms are shown in
Figure 4.4. This finding was also consistent with our previous data on SD rats treated
solely with Concord grape juice (Chen, Lobo et al. 2011). A comparison of major SGP
polyphenol metabolites are listed in Table 4.2.
There was a major peak shown in the brain extract tentatively assigned as a Q glucur
based on MRM Response (Figure 4.4.) and in line spectra (data not shown). However,
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assignment of the glucuronidation site was not possible at this time as isolation and
NMR analysis is required for complete assignment. All major polyphenol metabolites
including C 5 glucur, EC 5 glucur, 3’ OMeC 5 glucur, 3’ OMeEC 5 glucur, Res 3 glucur,
Q 3 glucur and MeO Q glucur were found in the extracts of plasma and brains for both
ZDF rats and their LN counterparts. No metabolites were detected in plasma and brain
extracts from control rats.
Major anthocyanins detected in plasma were malvidin (Mv), petunidin (Pt), peonidin
(Pn), cyanidin (Cy) and delphinidin (Dp) glucosides with structures depicted in Figure 4.3.
MRM chromatograms of anthocyanins from plasma were shown in Figure 4.5. There
were no detectable levels of anthocyanidin metabolic derivatives in the brain tissues of
SGP or control animals.
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Figure 4.2. Representative MRM chromatograms of major flavan 3 ol and resveratrol
metabolites from plasma and brain extracts.
MRM chromatogram is shown for C/EC 5 glucur (465.1 > 289.1 m/z), 3’ MeO C/EC 5
glucur (479.1 > 303.1 m/z) and Res 3 glucur (403.1 > 227.1 m/z) under negative
polarity. Peak identifications are: 1. C 5 glucur, 2. EC 5 glucur, 3. 3’ OMeC 5 glucur, 4.
3’ OMeEC 5 glucur and 5. Res 3 glucur.
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Figure 4.4. Representative MRM chromatograms of major Q metabolites from plasma
and brain extracts.
MRM trace is shown for Q glucur (479.1 > 303.1 m/z) and MeO Q glucur (493.1 >
317.1 m/z). Peak identifications were: 1. Q 3 glucur, 2. MeO Q glucur and 3. Tentatively
identified as Q glucur with glucuronidation in an unknown position.
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Figure 4.5. Representative MRM chromatograms of anthocyanin derivatives from
plasma extracts and Concord grape juice.
MRM transitions were: 493.1 > 331.1 for Mv 3 glucoside, 479.1 >317.1 for Pt glucoside,
465.1 > 303.1 Dp glucoside, 463.1 > 301.1 for Pn glucoside and 449.1 > 287.1 for Cy 3
glucoside. Peak identifications were: 1. Mv 3 glucoside, 2. Pt glucoside, 3. Dp glucoside,
4. Pn glucoside and 5. Cy 3 glucoside.
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Table 4.2. Comparison of major polyphenol metabolites detected in SD rats and ZDF rats
treated with SGP.
SGP

Flavan 3 ol

SD rats

ZDF rats

C 5 glucur

C 5 glucur

EC 5 glucur

EC 5 glucur

3’OMeC 5 glucur

3’OMeC 5 glucur

3’OMeEC 5 glucur

3’OMeEC 5 glucur
Q glucur (position unknown)

Flavonol

Anthocyanin

Resveratrol

Q 3 glucur

Q 3 glucur

MeO Q glucur

MeO Q glucur

Mv glucoside

Mv glucoside

Pt glucoside

Pt glucoside

Dp glucoside

Dp glucoside

Pn glucoside

Pn glucoside

Cy glucoside

Cy glucoside

Res 3 glucur

Res 3 glucur

Plasma Pharmacokinetics of SGP polyphenol metabolites in ZDF versus LN Rats
Eight hour plasma pharmacokinetic curves of flavan 3 ol metabolites in ZDF and LN
rats after 10 days of SGP treatment are shown in Figure 4.6. Plasma levels of four major
flavan 3 ol metabolites, C 5 glucur, EC 5 glucur and their methylated metabolites
peaked between 1.5 to 2.5 h for ZDF rats and their LN counterparts. This peak was
followed by a drop at 4 h for LN rats returning close to baseline by 8h post gavage. ZDF
rats exhibited a slower rate of elimination and return to baseline levels. ZDF rats
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exhibited a significantly diminished Cmax compared to their LN respectively for C 5 glucur
(p=0.0104), EC 5 glucur (p=0.0077), and their methylated metabolites (p<0.0001) (Table
4.3.).
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Figure 4.6. Plasma pharmacokinetic responses of flavan 3 ol metabolites.
No metabolites were detected in any control rats (n=4 /CNTL group).
Data was represented as mean ± SEM (n=8 /SGP group).
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Table 4.3. Plasma pharmacokinetic parameters of flavan 3 ol metabolites.
Treatment
C 5 glucur
EC 5 glucur
3’ OMeC 5 glucur
3’ OMeEC 5 glucur

ZDF SGP
LN SGP
ZDF SGP
LN SGP
ZDF SGP
LN SGP
ZDF SGP
LN SGP

AUC 0 8h
( mol/L*h)
76.3 16.7
93.4 11.0
59.7 13.5
81.2 11.3
25.1 13.5
108.1 6.7*
23.0 12.4
110.3 5.9*

Parameters
C max
( mol/L)
18.5 3.6
35.9 4.7*
15.5 2.8
31.3 4.3*
5.4 2.9
24.8 1.6*
4.9 2.6
24.1 1.8*

Tmax
(h)
2.3
1.5
2.1
1.6
1.8
1.8
2.0
1.9

0.5
0.2
0.4
0.2
0.2
0.2
0.0
0.1

Data was represented as mean ± SEM (n=4 /CNTL group and n=8 /SGP group).
‘*’ indicated significant difference between ZDF and LN rats with p<0.05.
Two major flavonol metabolites derived from Concord grape juice were Q 3 glucur
and its methylated glucuronide. Plasma level peaked ~ 1 h for Q 3 glucur at a Cmax of
8.11 ± 1.42 nmol/L for ZDF rats significantly lower than the Cmax of 15.41 ± 2.06 nmol/L
for their LN counterparts (Figure 4.7.; Table 4.4.). LN rats had MeO Q glucur peak before
1h whereas ZDF rats peaked between 2 to 4 h. However, both rodent models had the
same residual levels in circulation at 8 h post gavage. ZDF rats reached a Cmax at 14.29 ±
0.57 nmol/L which was 49% lower than the LN rats (Table 4.4.). This reduction was
significant for Q 3 glucur (p=0.0112) and for MeO Q glucur (p=0.0062).
Res 3 glucur plasma levels peaked between 2 to 4 h (Figure 4.7.) reaching a Cmax of
60.36 ± 6.32 mol/L for ZDF rats. As with other phenolics, this level was significantly
lower than levels observed in LN counterparts with a Cmax of 34.36 ± 3.48 mol/L
(p=0.0029) (Table 4.4.). After peaking, plasma levels in all rats gradully declined but
were not completely eliminated by 8 h after gavage. There was difference in the pattern
of elimination between ZDF and LN rats. LN rats showed a rapid decline in plasma
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concentration after the peak, while ZDF had a more gradual one. However, this
difference is not significant based on the values of elimination rate constant (ZDF vs. LN,
0.00 ± 0.04 vs. 0.18 ± 0.20 h 1) .
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Figure 4.7. Plasma pharmacokinetic responses of quercetin metabolites. No metabolites
were detected in any control rats (n=4/CNTL group).
Data was represented as mean ± SEM (n=8/SGP group).
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Figure 4.8. Plasma pharmacokinetic responses of resveratrol metabolites. No
metabolites were detected in any control rats (n=4/CNTL group).
Data was represented as mean ± SEM (n=8/SGP group).

Table 4.4. Plasma pharmacokinetic parameters of quercetin metabolites.
Parameters
Treatment
Q 3 glucur
MeO Q glucur

ZDF SGP
LN SGP
ZDF SGP
LN SGP

AUC 0 8h
(nmol/L*h)
28.6 2.7
50.7 7.3*
71.9 3.2
123.0 19.9*

Cmax (nmol/L)

Tmax (h)

8.2
15.4
14.3
27.8

0.6
1.3
2.5
0.8

1.4
2.1*
0.6
3.5*

Data was represented as mean ± SEM (n=4/CNTL group and n=8/SGP group).
‘*’ indicated significant difference between ZDF and LN rats with p<0.05.

0.1
0.4
0.8
0.2
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Table 4.5. Plasma pharmacokinetic parameters of resveratrol metabolites.
Parameters
Treatment
Res 3 glucur

ZDF SGP
LN SGP

AUC 0 8h
(µmol/L*h)
180.8 20.5
328.9 40.5*

Cmax (µmol/L)

Tmax (h)

34.4 3.5
60.4 6.3*

2.6 0.8
2.2 0.9

Data was represented as mean ± SEM (n=4/CNTL group and n=8/SGP group).
‘*’ indicated significant difference between ZDF and LN rats with p<0.05.

Bioavalability, defined as AUC0 8h, were significantly lower in ZDF rats than in LN, for
3’ OMeC 5 glucur (p<0.0001), 3’ OMeEC 5 glucur (p<0.0001) (Table 4.3.). In general,
AUC0 8h of 3’ OMeC 5 glucur, 3’ OMeEC 5 glucur and RES 3 glucur were ~77%, 79% and
45% decreased relative to the LN. Q 3 glucur (p=0.0193), MeO Q glucur (p=0.0368) and
Res 3 glucur(p=0.0057) were also significantly lower in ZDF rats than LN (Table 4.4. and
4.5.). This suggests impaired bioavailability for ZDF rats relative to the LN rats under the
conditions of the present study. Although C 5 glucur and EC 5 glucur did not
demonstrate significant differences from their LN counterparts (p=0.0969 and p=
0.0621), the concentrations still showed a diminished trend by 18% and 26% relative to
the LN rats.
Anthocyanin plasma profiles indicated a rapid rise between 0.25 to 1 h after SGP
administration for LN rats while maximum values were obtained between 0.25 to 1 h for
ZDF rats (Figure 4.8.). After reaching peak levels in plasma, Mv 3 glucoside, Pn glucoside
and Cy 3 glucoside concentrations gradually returned to baseline within 8 h
measurement in both groups. However, Dp glucoside exhibited a oblivious second peak
around 1 h for both groups possibly resulting from Dp glucoside being captured again
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leaving from intestinal epithelial cell into the portal circulation (Kay 2006). There were
no significant differences found between ZDF and their LN counterparts in AUC0 8h, Cmax
or Tmax for anthocyanins (Table 4.5.). Although it did not reach the criteria for
significance, there was a trend of delayed Tmax of 0.83 ± 0.58 h from ZDF rats on Mv 3
glucoside, Pt glucoside and Cy 3 glucoside compared to 0.25 ± 0.00 h from LN rats. The
delayed Tmax suggested slower gastrointestinal mobility may be an issue within this
diabetic model and merits further exploration.
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Figure 4.9. Plasma pharmacokinetic responses of key anthocyanins.
No metabolites were detected in any control rats (n=2 with two rats combined /CNTL
group).
Data was represented as mean ± SEM (n=3 with two rats combined /SGP group).
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Table 4.6. Plasma pharmacokinetic parameters of anthocyanins.
Parameters
Treatment
Mv 3 glucoside
Pt glucoside
Dp glucoside
Pn glucoside
Cy 3 glucoside

ZDF SGP
LN SGP
ZDF SGP
LN SGP
ZDF SGP
LN SGP
ZDF SGP
LN SGP
ZDF SGP
LN SGP

AUC 0 8h
(nmol/L*h)
2.3 0.5
2.7 0.5
1.6 0.1
1.9 0.3
2.1 0.4
2.6 0.3
2.4 0.6
2.8 0.6
1.9 0.5
2.2 0.5

C max (nmol/L)

Tmax (h)

0.9
1.0
0.6
0.7
1.3
1.7
0.8
1.0
1.2
1.5

0.8
0.3
0.8
0.3
0.8
0.8
0.3
0.3
0.8
0.3

0.3
0.2
0.1
0.1
0.5
0.2
0.3
0.2
0.5
0.3

0.6
0.0
0.6
0.0
0.3
0.3
0.0
0.0
0.6
0.0

Data was represented as mean ± SEM (n=2/CNTL group and n=3/SGP group).

Brain Distribution of SGP Polyphenols in ZDF versus LN Rats
There were no polyphenolic compounds detected in any control rats. There were no
anthocyanins found in brain tissues of SGP treated ZDF or LN rats. Considering we and
others have previously reported anthocyanins in brain tissues (Andres Lacueva, Shukitt
Hale et al. 2005; Passamonti, Vrhovsek et al. 2005; Talavera, Felgines et al. 2005; Kalt,
Blumberg et al. 2008; Milbury and Kalt 2010; Chen, Lobo et al. 2011), this observation
suggested that the brain levels were simply below the limit of detection (estimated at
0.42 pmol/g tissue for Mv glucoside and 0.82 pmol/g tissue for Cy glucoside).
Deposition levels of all other polyhphenols were at pmol/g range after dosing SGP for 10
days. Consistent with plasma data, ZDF rats exibited significantly lower brain
concentrations in flavan 3 ol, flavonol and resveratrol metabolites relative to LN
counterparts (Figure 4.9.). After nomalizing brain concentrations to SGP dose, brain
concentrations of all polyphenol metabolites from SGP were still greater in LN rats
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compared to ZDF rats (Table 4.6.). ZDF rats showed significantly lower brain
concentrations on C 5 glucur (p=0.0056), EC 5 glucur (p=0.0082), 3’ OMeC 5 glucur
(p=0.0114), 3’ OMeEC 5 glucur (p=0.002) and Res 3 glucur (p=0.0088) relative to LN
animals. Similarly, brain concentrations of MeO Q glucur (p=0.0009) and Q 3 glucur
(p=0.0267) for ZDF rats were significantly lower relative to their LN counterparts (Figure
4.9.). This data suggested that diabetic condition in ZDF rats negatively impact the
overall absorption and eventual brain deposition on all major grape polyphenol
metabolites. When normalized by SGP dose, all four flavan 3 ol metabolites in LN rats
still showed higher brain deposition levels compared to ZDF rats. Similar observation
was made on quercetin and resveratrol metabolites. Interestingly, flavan 3 ol
metabolites seemed to have preferable assess cross the blood brain barrier compared
to quercetin and resveratrol metabolites In both LN and ZDF rats (Table 4.6.).

102
100
80
60

LN
*

ZDF

*

*
*

pmol/g tissue

40
20
0
(±)C C5glucur
glucur

( ) EC
EC
5 glucur
glucur

3’
MeO C glucur
MeO EC glucur
3’OMeC
glucur 3’3’OMeEC
glucur

150

5

*

4
100
3
2

50

1

*

*
0

0
glucur
Q Qglucur

glucur MeO
glucur
QQ33 glucur
MeOQ Q
glucur

Res 33glucur
Res
glucur

Figure 4.10. Brain responses of flavan 3 ol,resveratrol and quercetin metabolites.
No metabolites were detected in control rats.
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(p<0.05).
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Table 4.7. Normalized Cmax, AUC and brain levels by SGP in LN and ZDF rats.

Cmax
(µM/mg)
12.926
9.737
8.914

Normalized by Dose
LN rats
AUC
( M*h/mg)
33.625
25.235
38.931

Brain
(nM/mg)
18.414
13.431
25.326

Cmax
(µM/mg)
6.678
4.820
1.934

3'OMeEC-5-glucur

7.477

34.266

15.987

1.523

7.132

6.709

Q-3-glucur
MeO-Q-glucur

0.345
0.622

1.137
2.757

8.875
5.827

0.183
0.320

0.642
1.137

3.877
2.913

Mv-glucoside
Pt-glucoside
Dp-glucoside
Pn-glucoside
Cy-glucoside

0.150
0.100
0.116
0.196
0.132

0.383
0.255
0.173
0.555
0.196

0.000
0.000
0.000
0.000
0.000

0.130
0.083
0.085
0.163
0.103

0.333
0.214
0.143
0.480
0.167

0.000
0.000
0.000
0.000
0.000

Res-3-glucur

1.068

5.818

1.988

0.608

3.198

0.865

Metabolite
C-5-glucur
EC-5-glucur
3'OMeC-5-glucur

Normalized by Dose
ZDF rats
AUC
Brain (nM/mg)
( M*h/mg)
27.474
6.410
18.553
5.274
9.037
10.317

Urinary Excretion of SGP Polyphenols in ZDF versus LN Rats
Urinary output from ZDF rats was significantly higher with average of 67.39±5.43 mL
compared to 4.43±0.32 mL for LN rats. Urinary excretion of polyphenols from SGP was
determined based on the sum of polyphenol excretion on day2, day 6 and day10. There
were no polyphenols found in baseline urine samples for all rats. After adjusted with
total urine volume, sum of each of polyphenol concentration in urine samples were
determined (Figure 4.10.). ZDF rats had a significant increase in urinary excretion of C 5
glucur (p=0.003), EC 5 glucur (p<0.0001) and 3’ OMeC 3 glucur (p=0.0002) and 3’OMe
EC 5 glucur (p=0.0002). Similar observation was made on Res 3 glucur (p=0.003), Q 3
glucur (p=0.002) and MeO Q glucur (p=0.04) that ZDF rats showed significantly higher
urinary excretion than LN rats. Anthocyanin excretion was significantly higher in ZDF rats
compared to LN rats with Mv glucoside (p=0.01), Pt glucoside (p=0.02), Dp glucoside
(p=0.001), Pn glucoside (p=0.002) and Cy glucoside (p=0.006).
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Figure 4.11. Urinary excretion of flavan 3 ol, resveratrol, quercetin metabolites and
anthocyanins.
Urine samples were collected from day 2, day 6, day 10 of the study.
Presence of asterisk indicates a significant difference between LN and ZDF groups
(p<0.05).
Data was represented as mean ± SEM (n=5 8/SGP group).

4.4

Discussion

In general, repeated SGP dosing for 10 days did not influence average body weight
gain, food intake and fasting blood glucose for ZDF or LN rats suggesting that SGP is safe
for repeated consumption.
The metabolite profiling on polyphenols from SGP was consistent with our previous
findings (Ferruzzi, Lobo et al. 2009; Vingtdeux, Giliberto et al. 2010; Ho, Ferruzzi et al.
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2012; Wang, Ferruzzi et al. 2012) in Sprague Dawley (SD) rats treated individually with
GSE, red wine or resveratrol suggesting that similar metabolites are found in both SD
and ZDF rodent models (Table 4.2.). Furthermore, the consistent metabolite profiles
also suggested that SGP treatment may not alter the individual polyphenol metabolism
when they were ingested simultaneously as a mixture (discussed in Chapter 3). While
this observation warrants future efficacy study in combining proven effective
polyphenols for prevention/therapy of AD, it nevertheless suggest that combination of
polyphenol sources in extract form may be viable delivery systems.
ZDF rats demonstrated lower plasma levels on major polyphenols from SGP. There is
a possibility that the lower bioavailability exhibited in ZDF SGP rats resulted from
heavier in body weight and therefore more blood volume. Polyphenol metabolites
present in plasma might be diluted with larger quantity of blood. Therefore, we
corrected AUC0 8h values to total blood volume according to the formula based on body
weights for rats (Lee and Blaufox 1985). The results showed that the significance
between ZDF SGP and LN SGP groups remained the same after corrected for blood
volume suggesting that bioavailability of polyphenol metabolites were not diluted by
total blood volume in the system.
It has been established that delayed gastric emptying is one of the GI complication
resulting from diabetic condition. The condition can be progressed to a clinical disorder
of gastroparesis due to complete loss of mechanical outlet that initiate GI muscle
movement (Stevens, Jones et al. 2013). It is interesting we observed that ZDF rats
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showed a trend of delayed Tmax on Mv 3 glucoside, Pt glucoside and Cy 3 glucoside
compared to that on LN rats. The delayed Tmax suggested delayed GI emptying which has
been demonstrated in type I and II diabetes models. For example, in a type I rodent
model, GI mobility delay was associated with loss of myenteric nitric oxide synthase
expression which negatively influenced the function of myenteric plexus (Demedts,
Masaoka et al. 2013). Studies investigated compounds or nutrients that may help
recover gastric emptying in type II diabetes rodents (Wu, Bound et al. 2013) and humans
(Seimon, Brennan et al. 2013) suggesting that it is a problem that needs cure. Based on
the knowledge that delayed gastric emptying is a major complication resulted from
diabetes, our data show for the first time that polyphenols, especially anthocyanins,
showed delayed Tmax presumably affected by such complication. Therefore, it can be
concluded that delayed gastric emptying is a contributing factor for poor polyphenol
absorption on diabetic animals, however, as anthocyanins can be effectively absorbed in
the gastric environment, delayed emptying was not a hindrance to the uptake of these
polyphenols.
Based on the results gathered from plasma data, plasma concentration of all
polyphenols including flavan 3 ols, resveratrol, quercetin metabolites and anthocyanins
are significantly lower than that in LN rats. It is reasonable to suspect that the low
plasma level results from low absorption or high urinary excretion. Our data on urinary
excretion confirmed that ZDF rats exhibiting high urinary excretion might be a major
factor that influence polyphenol absorption. Further investigation should be focus on
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intestinal mechanism of absorption and intestinal integrity and function from SGP of
ZDF and LN rats to fully explain the mechanism of the effect of diabetes on polyphenol
absorption.
Similar to the speculation we made in Chapter III that flavan 3 ol metabolites are
preferably selected to cross blood brain barrier and enter the brain after normalizing
brain concentrations to SGP dose in SD rats (see Chapter 3, Table 3.8.). The normalized
data shown in Table 4.6. pointed out similar observation that flavan 3 ol metabolites
enter the brain more efficiently compared to the other metabolites in a diabetic rat
model. Additionally, when comparing brain levels of major SGP metabolites, LN rats
showed higher brain concentrations on all SGP polyphenol metabolites compared to
ZDF rats after dose normalization. It has been suggested that the diabetic condition
might lead to morphological changes in blood brain barrier which further influences its
functionality. For example, it has been shown that diabetic state induced by
streptozotocin in rats had an increase in BBB permeability indicating a microvascular
leakage especially to small molecules (Huber, VanGilder et al. 2006). Another study
using MR (magnetic resonance) imaging showed an increase in BBB permeability in type
II diabetes patients (Starr, Wardlaw et al. 2003). BBB leakage in relation to type II
diabetes might explain low concentration of polyphenol metabolites in ZDF brain tissues
compared to LN brains presented in the present study. Since many neurodegenerative
diseases have been shown to have disrupted BBB structure which lead to functionality
breakdown (Ariga, Jarvis et al. 1998; Zlokovic 2002), the BBB leakage that results in low
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accumulation of polyphenol metabolites needs to be taken into account when
considering the proper usage of dose.
4.5

Conclusion

The goal of this study was to investigate the effect of diabetes on polyphenol
bioavailability. To our knowledge, this is the first study that has been conducted in a
diabetic rat model to investigate plasma and brain bioavailability of grape polyphenols
and their metabolites associated with AD modifying activities. Overall, ZDF rats had
diminished plasma bioavailability and brain deposition levels relative to their LN
counterparts. ZDF rats showed total urinary excretion on all polyphenols from SGP
which inversely correlated to plasma concentration. Connecting plasma and urine data,
it is reasonable to speculate that diabetes impaired SGP polyphenol absorption due to
excessive excretion from urine. Data from this study support the hypothesis that
diabetic condition may have a profound impact on the absorption, metabolism and
excretion of grape polyphenols. The mechanism behind these observations merits
further investigation including possible alteration of transport and intestinal function as
well as major phase II metabolizing enzymes that involve in grape polyphenols
transformation. The future direction will be to analyze the level of the same metabolites
from gastrointestinal contents as well as the intestines. This will further confirm
whether the diminished absorption observed here is due to differences in intestinal
transport or processing of polyphenols. With this data implicated, the dosage intended
to reach therapeutic efficacy should be adjusted to the disease condition.
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CHAPTER 5. PLASMA AND REGIONAL BRAIN BIOAVAILABILITY OF POLYPHENOLS
FROM APPLE, GRAPE SEED AND BILBERRY EXTRACTS IN A YOUNG SWINE MODEL

Abstract
Plant derived polyphenols have demonstrated the potential for neuroprotective
activities that may influence cognitive development and protection in both young and
aging brains. The goal of this project was to determine the bioavailability and regional
brain distribution of select polyphenols, including flavan 3 ol, flavonols and anthocynins
from apple/grape seed (GSE) and bilberry extracts. Weaning piglets were used as the
model of young brains. Animals were treated daily for 3 weeks with two polyphenol rich
products, an apple/GSE blend and a bilberry extract, in a physiological (27.5 mg of total
polyphenols/kg BW) and a pharmacological (82.5mg of total polyphenols/kg BW) dose
or with water as control. A 24 hour pharmacokinetic study was conducted and brain
tissues were harvested and segmented. LC MS/MS analysis confirmed presence of
major flavan 3 ol and flavonol metabolites including catechin 5 glucuronide (C 5 glucur),
epicatechin 5 glucuronide (EC 5 glucur), 3’methyl catechin 5 glucuronide (3’ OMeC 5
glucur), 3’methyl epicatechin 5 glucuronide (3’ OMeEC 5 glucur), quercetin glucuronide
(Q glucur) and methyl quercetin glucuronide (MeO Q glucur) in plasma and regional
brain segments from apple/GSE treated groups. Ten key anthocyanindin galactosides
and glucosides were detected in plasma and brain extracts from bilberry treated groups.
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Significant dose dependent increase was observed in plasma indicated by significantly
higher AUC in the high dose apple/GSE group on major flavan 3 ol metabolites. AUC0
1440min

in the unit of mol/L*min for high versus low apple/GSE groups are 27051 versus

8273 for C 5 glucuronide (p=0.01), 25282 versus 7887 for EC 5 glucuronide (p=0.006),
9662 versus 399 for 3’ OMeC 5 glucuronide (p=0.0004) and 3609 versus 158 for 3’
OMeEC 5 glucuronide (p=0.0007). Most anthocyanidin glycosides exhibit dose
dependent increase in the high dose bilberry group including delphinidin (Dp) (p=0.04),
cyanidin (Cy) galactosides (p=0.02) and petunidin (Pt) (p=0.03), peonidin (Pn) (p=0.03)
and cyanidin (Cy) glucosides (p=0.01). In the brain, significant dose dependent increase
was found in the cerebellum and frontal cortex in all major flavan 3 ol metabolites. All
anthocyanidin glycosides except for delphinidin, show a dose dependent increase in the
cerebellum.

5.1

Introduction

There is considerable evidence for the benefits of polyphenol rich foods and dietary
supplements in the prevention of age related neurodegenerative diseases (see review
in(Ebrahimi and Schluesener 2012)). While specific mechanisms remain elusive, it has
been proposed that protection against age related diseases by polyphenols may be due,
in part, to their antioxidant properties, their potential to increase of nitric oxide
production and through anti inflammatory mechanism (Campos Esparza Mdel and
Torres Ramos 2010; Albarracin, Stab et al. 2012). There is also a growing interest in the
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potential of polyphenols to promote healthy brain and cognitive development in young
population. However, there are few studies of the benefits of polyphenols in young
populations. Most investigations have focused on the prevention of injury in prenatal
life. For example, Loren et al. showed that maternal supplementation with pomegranate
juice protected hypoxic ischemic injury in rat pup’s brain (Loren, Seeram et al. 2005).
Narita et al. demonstrated that grape seed extract protected glutamate induced insults
in a primary neonatal mouse neuron culture (Narita, Hisamoto et al. 2011).
A key step in understanding the potential of polyphenols to promote healthy brain
development is the determination of dose response, bioavailability, metabolism and
tissue distribution of specific polyphenols and metabolites. However, limited data exists
on the estimation of polyphenol intake on infants and children. As far as polyphenols
intake in the young population, Gu et al. estimated ~68 mg/day of proanthocyanidins
intake in the age group of 2 5 years old, ~65mg/day in 6 11 years old, ~1.3mg/day in
infants (4 6 month) and ~26.9 mg/day in 6 10 month in the United States (Gu, Kelm et al.
2004). In an Australian population, total flavonoid intakes were estimated to be ~24,
~28 and ~40 mg/day in children in age groups 2 3, 4 7 and 8 11 years old (Johannot and
Somerset 2006). A recent study estimated anthocyanidin intake of ~4mg/day (median)
in older infants and toddlers aged 9 36 month old (Drossard, Alexy et al. 2011). Based
on these three studies, an estimated intake of flavonoids would be <100 mg/day in
infants and children. In this study, we used polyphenol rich apple/GSE and bilberry
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extracts, which are abundant in major flavonoids and anthocyanin glycosides was
appropriate for targeting infants and young children consumption.
Understanding of bioavailability, metabolism and tissue distribution of polyphenols
from fruits and vegetables is critical since the physiological impacts of polyphenols
depend on their delivery to target tissues. Previous investigations have identified key
dietary polyphenol forms that have the potential of penetrating the blood brain barrier
in animal models and whose metabolites may elicit neuroprotective effects (Vingtdeux,
Giliberto et al. 2010; Wang, Ferruzzi et al. 2012; Ho, Ferruzzi et al. 2013). This includes
flavonoids such as flavan 3 ols, flavonols and anthocyanidins derived from fruits. Apples
are highly abundant in flavonols especially quercetin derivatives including Q 3
galactoside and Q 3 glucoside (Lee, Kim et al. 2003). Grape seeds are rich in flavan 3 ols
primarily monomeric catechin (C) and epicatechin (EC) and polymeric procyanidins
(Hollecker, Pinna et al. 2009). Most berries are rich in anthocyanindin sugar derivatives
such as glucosides, galactosides and arabinosides (Latti, Riihinen et al. 2011; Liang, Yang
et al. 2012). A number of studies report bioavailability of these specific flavonoids from
different food stuffs in various species including humans (see review in (Scalbert and
Williamson 2000; Manach, Williamson et al. 2005)), rats (Nakagawa and Miyazawa 1997;
Abd El Mohsen, Kuhnle et al. 2002; Ferruzzi, Lobo et al. 2009; Prasain, Peng et al. 2009;
Serra, Macia et al. 2012), and pigs (de Boer, Dihal et al. 2005; Percival 2005; Bieger,
Cermak et al. 2008).
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To better understand the potential of these polyphenols to deliver neuroprotective
benefits in young populations, it is important to determine whether the distribution of
polyphenols and metabolites in the brain is uniform or if there are regional differences.
However, determination of brain distribution has often not been complete due to
analytical limitations and insufficient quantities of tissue. Ferruzzi et al. reported ~290
and ~576 pg/g of C, methyl catechin (MeO C) and EC, MeO EC in whole rat brain after
10 days of intragastric gavage of 50 150mg/kg BW of GSE for 10 days (Ferruzzi, Lobo et
al. 2009). Ishisaka et al. found ~40 pmol/g of Q aglycon and ~48 pmol/g of MeO Q after
feeding rats a quercetin containing diet at the dose of 200mg/kg BW for one month
(Ishisaka, Ichikawa et al. 2011). Bieger et al. found~0.02 nmol/g of Q aglycon in pig
brains after 4 weeks of quercetin containing diet consumed at the dose of 50 mg/kg BW
(Bieger, Cermak et al. 2008). A feeding trial in which, rats were put on 2% of blueberry
powder for 8 weeks resulted in detection of anthocyanidin aglycon in brain regions,
however the concentrations were not estimated (Andres Lacueva, Shukitt Hale et al.
2005). Milbury and Kalt detected ~0.7 to 0.9 nmol/kg tissue of anthocyanins and
glucuronides in brain regions after feeding pigs with 2% of blueberry diet for 8 weeks
(Milbury and Kalt 2010). More data is needed to correlate brain deposition of
polyphenols to their physiological functions in vivo.
Pigs are suitable model for nutrient studies that provide implications for human
nutrition. In spite of some external morphological differences between pigs and human,
their anatomy and physiology are similar (Patterson, Lei et al. 2008). The similarity in
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gastrointestinal (GI) structures between pigs and humans makes the pig a good model
to generate preliminary data for human nutrition studies (Patterson, Lei et al. 2008).
Pigs are omnivores like humans with similar absorption and metabolic processes.
Besides GI similarity, another advantage to using pigs over rodents for brain distribution
studies is the larger amount of brain material. The large available amount of tissue
makes it possible to determine differential distribution of polyphenols in different brain
regions.
We reported here on data obtained from bioavailability studies from piglets treated
with two polyphenol preparations, apple/GSE blend and bilberry extract, in high and low
doses. The major goals were: 1) to investigate plasma pharmacokinetic behavior and
dose response and 2) to determine regional brain distribution and dose response of
polyphenols derived from commonly consumed fruit extracts (apple, grape seed and
bilberry). This study provides evidence to suggest that consumption of physiological
dose of polyphenols can result in their accumulation in specific brain regions providing
as basis for future efficacy studies.

5.2

Materials and Method

Chemicals and Materials
(+) C, ( ) EC, procyanidin B1, B2 and Q 3 glucuronide authentic standards were
purchased from Sigma Aldrich (St. Louis, MO). All extraction and liquid chromatography
solvents were HPLC certified and were obtained from J.T. Baker (Phillipsburg, NJ). Mv 3
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glucoside chloride and Cy 3 glucoside chloride were purchased from ChromaDex (Irvine,
CA). Apple extract (Appl’in AFPOMM9080) was purchased from Diana Naturals (Antrain,
France) and GSE (OmniVin 20R) was from Ajinomoto OmniChem (Louvain la Neuve,
Belgium). The apple/GSE blend used in this present study was a mix at 2:1 ratio. Bilberry
extract (NutriPhy) was purchased from ChrHansen (Horsholm, Denmark).

Animals
All animal studies were conducted under guidance and with protocols reviewed and
approved by the Purdue University Animal Care and Use Committee. Forty commercial,
newly weaned piglets with body weight of 14 ± 0.5 pounds were used. After one week
of acclimation, piglets were randomly assigned to five treatment groups: 1) control
(CNTL), 2) high dose apple/GSE blend (high apple/GSE), 3) low dose apple/GSE blend
(low apple/GSE), 4) high dose bilberry extract (high bilberry) and 5) low dose bilberry
extract (low bilberry). Piglets were maintained on polyphenol free pelleted diet D01067
for growing swine (Research Diets, New Brunswick, NJ) with casein replacing soy protein
providing 308 kcal/g of pellet. In order to control the body weight gain and maintain
healthy growth, piglets were fed on 4% of their body weight for the first two weeks and
then 5% of their body weight for the remainder of the study (Carr 1998). The median
body weight of the pigs was used to calculate the food amount given to all piglets.
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Material Analysis
Analyses of extracts and diets was performed based on the method described in
(Song, Jouni et al. 2013) for apple/GSE blend and in (Song, Sapper et al. 2013) for
bilberry extract. In brief, both analyses were completed by a Waters 2695 Separations
Module with a Waters Xterra RP C18 column (2.1 x 100 mm, 3.5 m) at 0.3 mL/min flow
rate. The column was heated to 40

for apple/GSE and 35

for bilberry analysis. A

Waters ZQ MSD was used to detect phenolics with single ion responses (SIRs) in
apple/GSE including 289, 301 and 463 m/z to target C/EC, Q aglycon and Q 3 glucoside,
respectively. SIRs for bilberry were set at 303.8, 331.7, 287.5, 317.7 and 301.7 to detect
Dp, Mv, Cy, Pt and Pn, respectively. Total polyphenolic content of apple/GSE and
bilberry was determined to be 54% and 89% by Folin Ciocalteu assay.

Polyphenol Treatment
The target dose for young children will be 200 mg/day based previous reports (Gu,
Kelm et al. 2004; Johannot and Somerset 2006; Drossard, Alexy et al. 2011). In order to
accurately translate data from piglet to children, we adjusted the doses used in this
study using standard FDA conversions between animal and human equivalent dose (FDA
2005). The conversion gave a reasonable dose of 27.5 mg/kg BW in a piglet equaled to
200 mg/kg BW in a human child. This dose was estimated to be close to physiological
dose achievable by diet. A pharmacological/supplemental dose was designed to be 3
times higher (82.5 mg/kg) to resemble the effect of drug unachievable by food
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consumption. The amounts for treatments were calculated based on the total
polyphenol content of the two polyphenol rich preparations. The polyphenol
treatments were given every morning mixed with a small amount of food (~50 to 90g
depending on body weight) and water for total of three weeks. Piglets in the control
group received water mixed with plain food. Supplements were consumed within 2 to 3
minutes. After consuming their supplements, piglets were fed 2/3 of their daily food
allowance and the remaining 1/3 was fed in the afternoon.

Pharmacokinetic Study
In the last week of the study, the piglets were implanted with jugular vein catheters
(CX 2014S, BASi, West Lafayette, IN) based on the procedure described in (Marchant
Forde, Matthews et al. 2012) with minor modifications. In brief, piglets were
anesthetized with intramuscular injection of 0.025 mL/kg body weight of TKX (Telazol,
Ketamine and Xylazine) obtained from Lloyd Laboratories, Shenandoah, IA and
maintained under anesthesia with 2.5% of isoflurane with 3 L/min of oxygen. An incision
was made over the jugular fossa for the catheter placement. After checking for patency,
the incisions were closed. Piglets were injected with 1 mg/kg BW of 100 mg/mL
Banamine (PrevailTM, VETONE Inc. League City, TX) for post surgical analgesia. A second
dose of Banamine was given 8 h post surgery.
The day after surgery and following an overnight fast, a pharmacokinetic assessment
was initiated. A baseline blood sample was obtained and piglets were dosed with
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supplements mixing with pelleted diet and water. After individual polyphenol
treatments, blood was collected at the following predetermined time intervals:
immediately post treatment (~5minutes), 10, 20, 30, 45 minutes and 1, 1.5, 2, 3, 4, 6, 8,
12 and 24h post dose. All blood samples were drawn from the catheter, placed into
heparinized tubes and centrifuged at 6500 rpm for 10 min at 4

to separate plasma.

Plasma was collected and acidified with 1% ascorbic acid (w/v) in saline at 4:1 ratio,
purged with N2 and frozen. Food was return to piglets 1h after supplement dosing.

Body Weight, Food Intake and Liver Toxicity
Piglets’ body weights were monitored every other day and food intake was measured
every day throughout the study to ensure proper growth. After the final 24h blood draw,
piglets were dosed with one additional polyphenol treatment. One hour post dosing,
blood samples were drawn and serum was obtained. Serum was analyzed for liver
enzyme levels using the Kodak Ektachem 700 analyzer (Eastman Kodak Company,
Rochester, NY) to check for toxicity. Piglets were then euthanized with 1mL/10lbs BW of
Beuthanasia (Intervet/Schering Plough, UK). Blood was removed from brain tissue by
perfusion with ice cold saline into the descending aorta and heart. Six brain regions
including cerebellum (Ce), brain stem (St), medial frontal cortex (Co), hippocampus (Hi),
hypothalamus (Hy) and amygdala (Am) were collected within 15 minutes of euthanasia
and immediately frozen until analysis.
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Polyphenol Metabolites Extraction in Plasma and Brain Tissues
C/EC and Q metabolites and anthocyanin glycosides were extracted from plasma and
brain homogenates by solid phase extraction (SPE) using 1 mL Waters Oasis HLB
cartridges (Milford, MA) as previously described (Ho, Ferruzzi et al. 2013). In brief,
acidified plasma and methanolic brain extracts were loaded onto preconditioned SPE
cartridges. The cartridges were washed with 1 mL of 1.5M formic acid (v/v) followed by
1 mL of 5% aqueous methanol (v/v) for C/EC and Q metabolites and 2 mL of 2% formic
acid (v/v) for anthocyanidin derivatives. C/EC and Q metabolites were eluted with 2 mL
of 0.1% formic acid/methanol (v/v) and anthocyanidin derivatives were eluted with 2%
formic acid/methanol (v/v). Eluents were dried under vacuum at 37

. Dried extracts

were reconstituted with LC mobile phases for immediate analysis. For the bilberry
treated groups, regional brain tissues from two piglets were combined for anthocyanin
analysis. Amygdala parts from two piglets in the same apple/GSE group were combined
for C/EC and Q analysis.

Polyphenol Analysis of Plasma and Brain Tissues by LC MS/MS
Polyphenol analyses were performed on an Agilent 6400 Triple Quadrupole LC
MS/MS equipped with an electron spray ionization (ESI) source under multiple reaction
monitoring modes (MRM) as previously described in (Wang, Ferruzzi et al. 2012; Ho,
Ferruzzi et al. 2013) with minor modifications. A Waters XTerra RP C18 column (2.1 x
100 mm, 3.5 m) was employed with binary mobile phases of A: 0.1% aqueous formic
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acid (v/v) and B: 0.1% formic acid in acetonitrile (v/v). The column was heated to 30
and the system flow rate was 0.3 mL/min. The binary gradient to elute all phenolic
metabolites was: 10% B at 0 min, 40% B at 10 min, 95% B at 11 min and back to 10% B at
12 min to 18 min. Fragmentor voltage was set at 135V and collision energy was 17eV for
all compounds. ESI source conditions: gas temperature was 350 , drying gas flow was
11 l/min, nebulizer was 30 psi, sheath gas temp was 350 , sheath gas flow was 11
L/min, capillary voltage was 3500V and nozzle voltage was 1000V. For anthocyanin
analysis, the column was heated to 35

and the binary mobile phases were A: 2%

aqueous formic acid (v/v) and B: 0.1% formic acid in acetonitrile (v/v). The gradient was:
5% B at 0 min, 10% B at 10 min, 25% B at 30 min, 5% B at 31 min and continue on 5% B
to 35 min. ESI source condition setting was the same as described above. MRM
transitions of the targeted phenolics are shown in Table 5.1. Quantification of C/EC and
Q metabolites was based on MS peaks estimated using calibration curves constructed
from authentic C aglycon and Q 3 glucur standards. Quantification of Cy 3 glucoside
was calculated from a calibration curve constructed with authentic Cy 3 glucoside while
other anthocyanidin glycosides were based on Mv 3 glucoside.
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Table 5.1. MRM transition and ESI source polarity for flavan 3 ol, quercetin metabolites
and anthocyanidin glycosides.

Statistical Analysis
All data are presented as mean ± standard error of the mean (SEM). Pharmacokinetic
parameters including: 1) area under the plasma concentration versus time (AUC0 1440min)
were calculated using the linear trapezoidal rule, 2) the maximum plasma
concentrations (Cmax) and, 3) the time at Cmax (Tmax) were determined directly from the
pharmacokinetic curves of plasma concentration versus time. Statistical analyses were
performed using SAS 9.3 statistical analysis program (Cary, NC). Group differences in
body weight were analyzed by a repeated measurement model. Group differences on
food intake AUC, liver enzyme levels and brain regions within the same dose group were
determined by one way ANOVA with Tukey’s post hoc test. Differences between high
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and low dose groups within the same treatment for pharmacokinetic parameters and
brain concentrations were analyzed by Student’s t test. Non normal distributed data
were subjected to transformation with appropriate lambda value. Student’s t test were
applied to determine the significant difference between transformed data in high and
low dose groups. The significance was accepted at the level of <0.05.

5.3

Results

Polyphenol Contents of Treatment Materials
Primary polyphenols detected in 2:1 apple/GSE blend are depicted in Figure 5.1. The
major polyphenols found in apple/GSE blend included monomeric C, EC and Q 3
glucoside, Q aglycon with quantities of 21, 40, 16 and 0.93 mg/g of extract respectively.
Procyanidin B1 and B2 were determined to be 17 and 32 mg/g of extract. Other
polyphenols found in apple/GSE blend are shown with quantities in Table 5.2. Major
bilberry extract anthocynidin glycosides including galactoside, glucoside and arabinoside
derivatives were shown in Figure 5.2 and quantities in Table 5.2. The analysis data was
provided by Brian Song.

123
Table 5.2. Quantities of major flavonoids detected in 2:1 apple/GSE blend and major
anthocyanidin glycosides detected in bilberry extract.

Figure 5.1. LC MS separation of major polyphenols in 2:1 apple/GSE blend.
LC MS data shows the presence of C and EC (289m/z), Q 3 glucur (463m/z) and Q
aglycon (301m/z).
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Figure 5.2. LC MS separation of major anthocyanidin glycosides in bilberry extract in
aglycon forms.
LC MS data shows the presence of sugar derivatives in the order of galactoside,
glucoside and arabinoside for Pn (301.7m/z), Pt (317.7m/z), Cy (287.5m/z), Mv
(331.7m/z) and Dp (303.8m/z).
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Body Weight, Food Intake and Toxicity
The growth of the piglets was monitored by recording both body weight and food
intake. There was no significant difference in food intake between groups suggesting
that polyphenol treatments did not affect appetite. Body weight did not differ among
groups indicating that polyphenol treatments likely did not influence normal growth
during the 3 week period of this investigation (data not shown).
Liver enzymes including aspartate aminotransferase (AST), alkaline phosphatase (ALP)
and glutamyltransferase (GGT) as well as total bilirubin were determined in serum as
measures of potential toxicity of each extract (Table 5.3.). Reference ranges were based
values for commercial swine (Friendship, Lumsden et al. 1984). AST levels appeared to
be within normal range for all groups. The ALP of the high apple/GSE group was slightly
higher than the normal range (Table 5.3.). However, there was no statistically difference
between treatment groups. All polyphenol treatment groups showed higher levels of
GGT than the normal range while the control group was at the high end of the reference
range. There was no significant difference among groups in GGT levels.
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Table 5.3. Liver enzyme panel of piglets.

Characterization of major polyphenols in plasma and brain tissues of piglets treated
with apple/GSE and bilberry extract
Major flavan 3 ol and flavonol metabolites detected in plasma and brain extracts
from apple/GSE treated piglets included C/EC 5 glucur, 3’OMe C/EC 5 glucur (Figure
5.3.), Q glucur and MeO Q glucur (Figure 5.4.). The results confirmed that the C/EC and
Q polyphenols are in fact bioavailable from these extracts and specific metabolites
found in plasma can cross blood brain barrier and accumulate in brain tissue. The
assignment of the Q glucuronide remains to be completed. However, based on
comparison with authentic Q 3 glucuronide standard, we can eliminate the
glucuronidation at position 3 as the likely structure. MeO Q glucuronide was detected in
some regional brain extracts but the level was below LOQ (1.70 pg of Q 3 glucuronide
on column).
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Figure 5.3. Representative MRM chromatograms of flavan 3 ol metabolites in plasma
and brain extracts from apple/GSE treated piglets.
MRM chromatogram is shown for C/EC 5 glucur (465.1 > 289.1 m/z) and 3’OMe C/EC
5 glucur (479.1 > 303.1 m/z) under negative polarity. Peaks identifications are: 1. C 5
glucur, 2. EC 5 glucur, 3. 3’ OMeC glucur and 4. 3’ OMeEC glucur.
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Figure 5.4. Representative MRM chromatograms of major Q metabolites in plasma and
brain extracts from apple/GSE treated piglets.
MRM trace is shown for Q glucur (479.1 > 303.1 m/z) and MeO Q glucur (493.1 >
317.1 m/z) under positive mode. Peak identifications were: 1. tentatively identified as
Q glucur and 2. MeO Q glucur. MeO Q glucur was present in some brain extracts but
the level was < LOQ.

Ten key anthocyanidin glycosides including Mv , Pt , Dp , Pn, and Cy galactosides and
glucosides were detected in plasma and brain extracts from bilberry treated piglets
(Figure 5.5.). Retention time on anthocyanidin galactosides and anthocyanidin
glucosides with the same MRM transition (Table 5.1.) were tentatively determined
based on previous reports (Zhang, Kou et al. 2004; Wu and Prior 2005; Vafeiadou,
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Vauzour et al. 2009; Ha, Lee et al. 2010). Based on information from previous reports
and validation with authentic standards of Mv and Cy 3 glucosides, the tentative
identification of the peaks were assigned in the order of anthocyanidin galactosides
followed by anthocyanidin glucosides in plasma and brain extracts from bilberry treated
piglets.
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Figure 5.5. Representative MRM chromatograms of anthocyanidin glycosides in plasma
and brain extracts from bilberry treated piglets.
MRM transitions were: 493.1 > 331.1 for Mv galactoside/glucoside, 479.1 >317.1 for
Pt galactoside/glucoside, 465.1 > 303.1 Dp galactoside/glucoside, 463.1 > 301.1 for Pn
galactoside/glucoside and 449.1 > 287.1 for Cy galactoside/glucoside. Peak
identifications were: 1. Mv 3 O galatoside, 2. Mv 3 O glucoside, 3. Pt galactoside, 4. Pt
glucoside, 5. Dp galactoside, 6. Dp glucoside, 7. Pn galactoside, 8. Pn glucoside, 9. Cy
galactoside and 10. Cy glucoside.
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Dose effect on plasma pharmacokinetics of polyphenols from apple/GSE or bilberry
treated piglets
24 hour pharmacokinetic curves of C and EC metabolites are illustrated in Figure 5.6.
Plasma reached peak concentrations ~85 to 95 min for C/EC 5 glucuronide and ~120 to
145 min for 3’OMe C/EC 5 glucuronide (Table 5.4.) and were gradually eliminated from
plasma within 24 h (Figure 5.6). Cmax of C 5 glucuronide and EC 5 glucuronide were
determined to be 165 and 158 mol/L respectively in the high apple/GSE group and
were significantly higher than low apple/GSE group (p=0.008 and p=0.005). For 3’OMe
C glucuronide and 3’OMe EC glucuronide, Cmax values were determined to be 35 and 13
mol/L respectively for High apple/GSE group which were significantly higher than low
apple/GSE group (p=0.0001 and p=0.0003) (Table 5.4). The dose dependence of plasma
response for four major flavan 3 ol metabolites were further confirmed by significantly
higher AUC0 1440min in high apple/GSE group compared to the low dose group with
p=0.01, 0.006, 0.0004 and 0.0007 for C 5 glucuronide, EC 5 glucuronide, 3’OMe C
glucuronide and 3’OMe EC glucuronide, respectively (Table 5.4).
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Figure 5.6. Plasma pharmacokinetic responses of flavan 3 ol metabolites from piglets
treated with high or low dose of apple/GSE for 3 weeks.
No metabolites were detected in any piglets from control group (n=5).
Data was represented as mean ± SEM with n=6 piglets per treatment group.

Table 5.4. Pharmacokinetic parameters of flavan 3 ol metabolites in plasma from piglets
treated with high or low dose of apple/GSE for 3 weeks.
C-5-glucur

EC-5-glucur

3’-OMeC-5-glucur

3’-OMeEC-5-glucur

Treatment
CNTL
High apple/GSE
Low apple/GSE
CNTL
High apple/GSE
Low apple/GSE
CNTL
High apple/GSE
Low apple/GSE
CNTL
High apple/GSE
Low apple/GSE

Parameters
AUC0-1440min ( mol/L*min)
ND
27051.8 4883.5*
8273.5 987.7
ND
25282.0 3950.5*
7887.5 985.8
ND
9662.8 1128.4*
399.2 46.5
ND
3609.2 471.1*
158.6 22.6

Cmax ( mol/L)
ND
165.8 27.8*
50.8 8.3
ND
158.3 24.4*
47.1 7.9
ND
35.4 3.2*
1.5 0.1
ND
13.4 1.4*
0.6 0.1

T max (min)
ND
90.0 7.7
85.0 12.0
ND
90.0 7.8
95.0 12.0
ND
135.0 21.6
120.0 13.4
ND
145.0 16.3
125.0 12.0

No metabolites (ND) were detected in any piglets from control group (n=5).
Data was represented as mean ± SEM (n=6/treatment group).
‘*’ indicated significant difference between high and low dose groups with p<0.05.
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Plasma pharmacokinetic profiles of Q glucuronide and MeO Q glucuronide are
illustrated in Figure 5.7. Plasma Q glucur showed peak concentrations ~17 to 23 min and
was gradually eliminated from the system by 24 h. There was no significant difference
found between dose groups on Cmax on Q glucur, nor on AUC0 1440min (Table 5.5.). MeO
Q glucuronide exhibited peak concentration at ~26 min for the high dose group and ~57
min for low dose group reached Cmax of 3.33 and 1.13 nmol/L on high and low apple/GSE
group, respectively (Table 5.5.).
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Figure 5.7. Plasma pharmacokinetic responses of quercetin metabolites after piglets
were treated with high or low dose of apple/GSE for 3 weeks.
No metabolites were detected in any piglets from control group (n=5).
Data was represented as mean ± SEM (n=6 piglets/treatment group).
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Table 5.5. Pharmacokinetic parameters of quercetin metabolites in plasma from piglets
treated with high or low dose of apple/GSE for 3 weeks.

No metabolites (ND) were detected in any piglets from control group (n=5).
Data was represented as mean ± SEM (n=6/treatment group).
‘*’ indicated significant difference between high and low dose groups with p<0.05.

Plasma pharmacokinetic profiles of anthocyanidin galactoside and –glucosides are
illustrated in Figure 5.8. All anthocyanidin derivatives plasma concentrations reached a
maximum between ~40 to 115 min after polyphenol ingestion (Table 5.6.). Our results
were consistent with other reports demonstrating that anthocyanins were rapidly
absorbed in both the gastric and upper small intestinal compartments of the GI tract as
intact glycosides (Passamonti, Vrhovsek et al. 2003; Talavera, Felgines et al. 2003). Cmax
of individual anthocyanidin galactosides ranged from 12 to 121 pmol/L in plasma in high
bilberry group with Cy galactoside being the highest. All five anthocyanidin galactosides
demonstrated significantly higher Cmax in the high bilberry group than in the low bilberry
group except for Mv glucosdie only showing a trend toward significance (Table 5.6.).
AUC0 1440min of Mv , Dp and Cy galactoside in high bilberry group were significantly
higher than those in low bilberry group. Cmax of key anthocyanidin glucosides including
Pt , Dp , Pn and Cy glucoside ranged from 30 to 223 pmol/L in high bilberry group
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which were found to be significantly higher than those in low bilberry group (Table 5.6.).
Cmax of Mv glucoside only showed a trend toward to significance (p=0.08). Pt , Pn and
Cy glucoside in high bilberry group had significantly higher AUC0 1440min compared to low
bilberry group. For Mv (p=0.05) and Dp glucoside (p=0.06), there was a trend toward
significant differences in AUC (Table 5.6.). Overall, there was a dose dependent increase
in plasma response from high compared to low bilberry groups across all five key
anthocyanidin glucosides detected in plasma determined by AUC0 1440min and Cmax (Table
5.6.).
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Figure 5.8. Plasma pharmacokinetic responses of major anthocyanidin glycosides
including galactosides and glucosides after piglets were treated with high or low dose of
bilberry extract for 3 weeks.
No metabolites were detected in any piglets from control group (n=5).
Data was represented as mean ± SEM with n=6 piglets per treatment group.
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Table 5.6. Pharmacokinetic parameters of anthocyanidin glycosides in plasma from
piglets treated with high or low dose of bilberry extract for 3 weeks.

Mv-galactoside

Pt-galactoside

Dp-galactoside

Pn-galactoside

Cy-galactoside

Mv-glucoside

Pt-glucoside

Dp-glucoside

Pn-glucoside

Cy-glucoside

Treatment
CNTL
High Bilberry
Low Bilberry
CNTL
High Bilberry
Low Bilberry
CNTL
High Bilberry
Low Bilberry
CNTL
High Bilberry
Low Bilberry
CNTL
High Bilberry
Low Bilberry
CNTL
High Bilberry
Low Bilberry
CNTL
High Bilberry
Low Bilberry
CNTL
High Bilberry
Low Bilberry
CNTL
High Bilberry
Low Bilberry
CNTL
High Bilberry
Low Bilberry

Parameters
AUC 0-1440min (pmol/L*min)
ND
1700.3 925.4*
9.3 8.0
ND
1325.6 816.6
59.7 49.2
ND
4747.6 1420.6*
931.6 484.9
ND
3782.5 1123.8^
1187.8 504.3
ND
22170.1 4437.9*
7153.2 2997.3
ND
4597.4 1767.9^
58.6 37.1
ND
4251.3 1351.2*
376.4 181.9
ND
7905.5 2527.0^
1697.0 696.4
ND
12553.8 3586.5*
3044.2 1385.4
ND
35391.3 7847.4*
10188.4 3307.6

C max (pmol/L)
ND
17.2 9.1*
0.2 0.2
ND
12.7 3.9*
1.0 0.6
ND
32.0 5.8*
12.5 4.2
ND
23.3 3.8*
9.9 2.9
ND
121.1 18.9*
41.2 11.7
ND
60.6 26.7^
0.9 0.6
ND
39.3 12.6*
4.8 1.6
ND
57.3 13.2*
18.1 3.0
ND
93.27 18.5*
23.00 6.3
ND
223.5 36.8*
78.5 19.8

T max (min)
ND
58.0 13.0
NA
ND
83.0 35.0
NA
ND
99.0 33.0
65.0 17.0
ND
57.0 15.0
87.0 18.0
ND
52.0 15.0*
115.0 16.0
ND
44.0 7.0
40.0 12.0
ND
52.0 15.0
85.0 29.0
ND
62.0 19.0
79.0 18.0
ND
44.0 8.0
82.0 17.0
ND
40.0 9.0
52.0 19.0

Transformed data: Mv galactosid (AUC0 1440min, Cmax and Tmax; Pt galactoside (AUC0
1440min); Pn galactoside (AUC0 1440min), Cy galactoside (AUC0 1440min); Mv glucoside (Cmax
and Tmax), Pt glucoside (AUC0 1440min).
No metabolites (ND) were detected in any piglets from control group (n=5).
Data was represented as mean ± SEM with n=6 piglets per treatment group.
‘*’ indicated significant difference between high and low dose groups with p<0.05.
‘^’ indicated a trend toward significant difference between high and low dose groups
with p<0.01.
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Regional differences in brain distribution of polyphenols from apple/GSE or bilberry
treated piglets
In order to determine the potential for targeting of individual brain regions, the
polyphenol metabolite content across six brain regions was analyzed for both high and
low dose group. Within the high dose apple/GSE group (Figure 5.9.), cerebellum showed
significantly higher deposition levels of C 5 glucuronide and 3’OMe C/EC glucuronide
than all other brain regions (p<0.0001). The same pattern was observed in the low dose
apple/GSE group in that cerebellum showed significantly higher deposition levels of C 5
glucur and 3’OMe C/EC glucuronide than all other brain regions (p<0.0001). For EC 5
glucur, however, cerebellum showed significantly higher deposition level compared to
hippocampus (p=0.02) and hypothalamus (p=0.01), but not to brain stem, frontal cortex
and amygdala for both dose groups.
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Similarly, the levels of anthocynidin glycosides were compared across six different
brain regions within the high and low bilberry group (Figure 5.10.). Within low dose
bilberry group, Mv galactoside and Mv glucoside were detected in cerebellum, brain
stem and frontal cortex but there was no significant difference between regions. Pt
galactoside was not detected in any brain region in the low dose bilberry group whereas
Pt glucoside was only detected in brain stem in one piglets and therefore, did not
significantly differ from other regions (p=0.46). Dp galactoside and Dp glucoside were
detected in brain stem but did not significantly differ from other regions. Pn galactoside
and Pn glucoside was detected in brain stem which significantly differed from other
regions (p=0.02).There were no regional differences in Pn galactoside. Cy galactoside
was detected in cerebellum, brain stem and frontal cortex but no significant differences
were observed between regions (p=0.08). Cy glucoside was detected in cerebellum and
brain stem and there was no significant difference observed between regions.
When comparing brain deposition levels across brain regions within high bilberry
group (Figure 5.10.), cerebellum was observed to have significantly higher deposition
levels of Mv galactoside, Mv glucoside, Pt galactoside, Pt glucoside, Pn galactoside, Cy
galactoside and Cy glucoside than other regions (all with p<0.0001). With Pn glucoside,
cerebellum was determined to have a significantly higher deposition level than all other
regions and brain stem had significantly higher deposition level than hippocampus,
hypothalamus and amygdala but did not differ from frontal cortex (Figure 5.10.). There
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was no significant difference shown across regions in Dp galactoside (p=0.11) or Dp
glucoside (p=0.11).
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Dose effect on brain distribution of polyphenols from apple/GSE or bilberry treated
piglets
When comparing polyphenol metabolite levels in brain tissues between high and low
doses within the same treatment (Figure 5.11.), there was a dose response dependent
increase of C 5 glucur content in cerebellum (p=0.04), frontal cortex (p=0.01) and a
trend in brain stem (p=0.09). On EC 5 glucur, the dose response was significant in
frontal cortex (p=0.02) and showed a trend for increase with high apple/GSE treatment
in hippocampus (p=0.07). For 3’OMe C glucur, there was a dose response in cerebellum
(p=0.01) and frontal cortex (p<0.0001) and a trend in hypothalamus (p=0.08). For
3’OMe EC glucur, the dose response was significant in cerebellum (p=0.01), frontal
cortex (p<0.0001), hypothalamus (p=0.05) and showed a trend in amygdala (p=0.08).
The dose dependent increase in brain tissue content was significant for Q glucur in
cerebellum (p=0.01), brain stem (p=0.03), hippocampus (p=0.01) and hypothalamus
(p=0.04) shown in Figure 5.11. Interestingly, there was no quantifiable MeO Q glucur
found in brain extracts from apple/GSE treated piglets.

143
C 5 glucur
2000

*
High apple/GSE
Low apple/GSE

1500

1500
1000

1000

pmol/g tissue

500

500

*

Ce

St

Co 1 Hi

Hy

Ce

Am

3’ OMeC 5 glucur

600
*

St

Co 1 Hi

Hy

Am

3’ OMeEC 5 glucur

600
500

400

400

300

300

200

200
*

100

*

100

*

*

0

0
Ce

St

2
1.5

*

0

0

500

EC 5 glucur

2000

Co 1 Hi

Hy

Am

Ce

St

Co 1 Hi

Hy

Am

Q glucur
*

1

*
*

*

0.5
0
Ce

St

Co 1 Hi

Hy

Am

Figure 5.1 . Dose differences of brain deposition of flavan 3 ol and quercetin
metabolites from piglet treated with high and low doses of apple/GSE for 3 weeks.
Asterisk represented significance between high and low dose groups within each brain
region.
Abbreviations: cerebellum (Ce), brain stem (St), frontal cortex (Co), hippocampus (Hi),
hypothalamus (Hy) and amydgala (Am).
Data was presented as mean ± SEM (n=6 per brain region).
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For bilberry anthocyanins, a significant dose dependent increase was only observed in
cerebellum for select anthocyanidin galactosides (Figure 5.12.), including Mv
galactoside (p=0.02), Pt galactoside (p=0.002), Pn galactoside (p=0.002), and Cy
galactosides (p<0.04) but not Dp galactoside (p=0.18). Dose dependence in cerebellum
was also significant for Mv glucoside (p=0.0153), Pt glucoside (p=0.0047), Pn glucoside
(p=0.038) and Cy glucosides (p=0.0118) but not Dp glucoside (p=0.1845). In other brain
regions including brain stem, frontal cortex, hippocampus, hypothalamus and amydgala,
there was no significant dose effect between the high and low dose groups. This is likely
due to the no detectable anthocyanins in the low bilberry group that results in the
statistically non significance between groups.
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5.4

Discussion

Limited information is currently available on polyphenol bioavailability in infants or
children. Furthermore, very little is known regarding specific distribution patterns of
polyphenol metabolites in the brain. With growing interest in understanding the role
polyphenols may play in promoting healthy brain development and function, the
current study was designed to investigate both plasma pharmacokinetics and regional
brain deposition of key polyphenol metabolites in young piglets treated with apple/GSE
or bilberry extract at two dose levels.
The most abundant polyphenol form in grape seed and apple fruit or extract are the
proanthocyanidins including C and EC in monomeric and polymeric forms (Table 5.2.).
The detection of flavan 3 ol metabolites in piglet plasma and brain extracts in this study
is consistent with previous findings in Sprague Dawley (SD) rats (Wang, Ferruzzi et al.
2012). What we found in the SD rat plasma and brain tissue dosed for 10 days with 17 or
28.3 mg/kg body weight of monomeric or polymeric C/EC fractions of GSE, the same C
and EC metabolites as those found in pigs suggesting that the similar C and EC
metabolites are generated by both species and distributed in the brain. The monomeric
fraction of C/EC improved cognitive function in Tg22576 Alzheimer’s disease (AD) model
mice (Wang, Ferruzzi et al. 2012). The presence of similar C and EC metabolites in piglet
plasma and brain tissue suggest that these compounds may be candidates for
subsequent studies focused on brain specific benefits in young healthy animal models.
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We have previously found Q 3 glucur in plasma and brain extracts from SD rats
chronically treated with Cabernet Sauvignon for 10 days. Q 3 glucur was found to be the
compound responsible for reducing

amyloid peptides in a primary neuron culture

from Tg2576 Alzheimer’s model mice (Ho, Ferruzzi et al. 2013). However, in the current
study, a Q glucur with unknown position of glucuronidation was found in piglets
suggesting the possibility of a different metabolite profile between species. Many
studies have demonstrated that the position sites for glucuronidation on Q glucur were
3, 4’ or 7 positions. For example, Gee et al. reported that in a SD rat gut model, Q 3
glucur and Q 7 glucur were detected in mucosal tissue and within serosal compartment
(Gee, DuPont et al. 2000). Moon et al. detected Q 3 glucur and Q 4’ glucur in rat plasma
20 min after an oral dose of 250mg/kg body weight of pure quercetin (Moon, Tsushida
et al. 2001). In human feeding trials, the main quercetin metabolites detected in human
plasma were Q 3 glucur (Day and Williamson 2001; Janisch, Williamson et al. 2004).
However, there are no data on quercetin metabolites in pigs since the majority of the
studies deconjugated metabolites to the aglycon by incubating samples with
glucuronidase (Ader, Wessmann et al. 2000; Lesser, Cermak et al. 2004; de Boer, Dihal
et al. 2005; Bieger, Cermak et al. 2008). Our data demonstrated the first time the major
quercetin metabolite detected in pig plasma and brain extract was not Q 3 glucur and
may therefore be speculate to position and suggest further study.
One consensus in the discussion of neuroprotective properties of polyphenols is that
polyphenols need to cross the blood brain barrier and localize in brain tissues to exert
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their benefits. Most studies used rodent models to determine polyphenol
concentrations in brain (Percival 2005; Ferruzzi, Lobo et al. 2009; Del Bo, Ciappellano et
al. 2010; Juan, Maijo et al. 2010; Serra, Macia et al. 2012) since human brains are nearly
impossible to obtain. Recently, there has been an increasing numbers of reports using
larger animals for this purpose. Kalt et al. found ~0.66 and 0.88 pmol/g of anthocyanins
in pig cerebellum and frontal cortex after the pigs were fed on 4% blueberry diet for 4
weeks (Milbury and Kalt 2010). Their follow up study detected ~0.7, 0.87, 0.92 pmol/g
of anthocyanins and glucuronides combined in frontal cortex, cerebellum and midbrain
after pigs were fed on 2% blueberry diet for 8 weeks (Milbury and Kalt 2010). Our data
on regional brain levels of anthocyanidin derivatives were estimated between 0 to 3
pmol/g depending on brain regions and compounds after piglets were dosed with
bilberry extract for 3 weeks. Furthermore, the brain tissues used in the current study
were harvest after the piglets were perfused with ice cold saline to be obtained blood
free while this may not be the case in previous studies where tissues may have only
been rinsed and not perfused (Milbury and Kalt 2010). Residual blood in tissues has
been shown to greatly influence polyphenol concentrations and often need to be
corrected for accurate determination (Friden, Ljungqvist et al. 2010).

5.5

Conclusion

To our knowledge, only limited information exists on regional brain distribution of
anthocyanins, flavan 3 ols, flavonols and their metabolites. In the present study, a swine
model which provided adequate brain tissue to study the regional differences in levels
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of key polyphenols from apple/GSE and bilberry was applied to characterize flavan 3 ol,
quercetin metabolites and anthocyanidin glycoside kinetics in plasma and distribution in
brain tissues. Using both a high or low dose of apple/GSE blend or bilberry extracts for 3
weeks, we confirmed similar flavan 3 ol metabolites in blood and brain tissues to those
reported in rodent models (Wang, Ferruzzi et al. 2012). Furthermore, flavan 3 ol
metabolites and quercetin metabolites were found in all six regions regardless the dose
suggesting that these polyphenols were able to cross blood brain barrier even in a low
dietary dose range. In contrast, anthocyanin derivatives were not able to be detected in
brain regions in a low dose treatment suggesting the levels were below LOD (0.4 pg on
column for both Cy 3 and Mv 3 glucoside). Further examination on brain deposition of
polyphenols across brain region demonstrated that cerebellum may be a primary site of
accumulation for flavan 3 ol, quercetin metabolites and anthocyanidin derivatives.
Future efficacy studies might need to consider the differential deposition of polyphenols
in brain regions to optimize the dose consideration.
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CHAPTER 6.

CONCLUSION AND FUTURE DIRECTIONS

6.1

Overall Conclusion

Alzheimer’s disease (AD) is projected to affect 5 billion Americans by the year 2050
(Hebert, Weuve et al. 2013). Its severity and prevalence called for immediate attention
for research to find a cure. Epidemiological studies have correlated the consumption of
fruits and vegetables and other beverages rich in polyphenols to the decreased risk for
age related neurodegenerative disorders (Orgogozo, Dartigues et al. 1997; Truelsen,
Thudium et al. 2002; Scarmeas, Stern et al. 2006; Letenneur, Proust Lima et al. 2007;
Scarmeas, Stern et al. 2009). There is increasing evidence showing the benefits of
flavonoids including GSE (Wang, Ho et al. 2008; Wang, Thomas et al. 2009), grape juice,
wine (Wang, Ho et al. 2006; Ho, Chen et al. 2009) and resveratrol (Marambaud, Zhao et
al. 2005) in in vitro and in vivo AD mouse model supporting their A lowering effects.
Since neuroprotection and preservation are the major actions of polyphenols to
counteract neurodegeneration, there has been growing interests in the effects of
polyphenols on neuron development in infants and young children. However, the
evidence of the effect of polyphenols on healthy young groups is lacking. In order to
gain insights into the therapeutic effects of polyphenol rich fruits extracts in brain
health in the elderly and the young, it is essential to characterized the bioactives, their
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absorption profiles and factors that influence bioavailability. This dissertation is aimed
to fill that knowledge gap with a special focus on bioavailability of polyphenols and their
implications for brain health.
The overall objective of this research was to study the bioavailability, metabolism and
brain distribution of the major flavonoids and stilbenoid from polyphenol rich fruit
products and extracts including GSE, Concord grape juice, resveratrol, apple and bilberry
extracts. The absorption and brain profiles of SGP (mixture of GSE, juice and resveratrol)
were evaluated as functions of diabetogenic diet and diabetic condition in rodent
models. To extend the possible neuroprotection effects to the young, a weaning piglet
model was used to investigate bioavailability of GSE/apple and bilberry extracts and
their brain deposition levels. Regional brain accumulation differences were also
determined.
In summary, Chapter 3 concluded that similar metabolites were found in plasma and
brain tissues when polyphenol rich extracts were treated individually or simultaneously
as SGP in a Sprague Dawley rat model. The impact of 3 weeks of diabetogenic diet
feeding on polyphenol absorption and brain deposition levels were minimum. Based on
the data obtained from the first study, fat composition in diet can be eliminated as a
confounding factor in regard to polyphenol absorption. Following upon on the first
study, Chapter 4 highlights the effects of the diabetic condition on the bioavailability of
the same polyphenolic preparation (SGP) in a Zucker diabetic rat model. Similar
polyphenol metabolite profiles were found in both healthy SD and diabetic rat models.
We concluded that the diabetic condition significantly decreased plasma bioavailability
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and brain deposition of flavan 3 ol, quercetin and resveratrol metabolites. We
suspected that the decreased polyphenol absorption was due to excessive urinary
excretion in Zucker diabetic rats. Taken together, Chapter 3 and 4 suggested that 3
weeks of diabetogenic diet may minimally affected polyphenol bioavailability, however,
the diabetic condition drastically decreased polyphenol absorption and brain
distribution possibly to due the heavy excretion in urine. Interestingly, after normalized
by SGP dose, flavan 3 ol metabolites demonstrated high brain concentrations in both
healthy Sprague Dawley and diabetic rat models compared to other polyphenol
metabolites including quercetin, resveratrol metabolites and anthocyanins. This is
exciting since this data indicted that flavan 3 ol metabolites had preferable assess into
the brain compared to other polyphenol sources suggesting that flavan 3 ol metabolites
are promising candidates for AD prevention.
Chapter 5 used a piglet model to represent young children to investigate the
bioavailability of GSE/apple and bilberry extracts in either a physiological or a
pharmacological dose. Flavan 3 ol, quercetin metabolites and anthocyanins were the
major bioactives circulating in the blood and targeted brains even on a physiological
dose which was determined to be achievable by supplements. Additionally, differences
on polyphenol accumulation in brain regions with cerebellum being the highest on
deposition levels of flavonoid metabolites suggested that these bioactives showed
preferable access into cerebellum.
In conclusion, bioavailability of polyphenols from SGP (GSE, Concord grape juice
and resveratrol) derived metabolites (flavan 3 ols, quercetin, resveratrol and
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anthocyanins) can be negatively affected by the diabetic condition but not by
diabetogenic diet under the treatment conditions used in this research. This observation
implied that disease condition should be given great consideration when recommending
the dosage of dietary supplements to patients. On the other hand, the same classes of
flavonoids metabolites derived from GSE/apple and bilberry extracts were found
bioavailable in a young piglet model. Concentrations in plasma and brain were found to
be dose dependent for flavan 3 ol metabolites and anthocyanins but not for quercetin
metabolites. Differential deposition of flavonoids in brain regions suggesting that
cerebellum is a preferred site for accumulation.

6.2

Future Directions

Our data demonstrated the first time that the diabetic condition negatively influences
flavonoid and stilbenoid absorption. While the data are promising, the speculation on
the mechanism of whether the impaired absorption of flavonoids in ZDF rats is
entirely due to excessive excretion through urine needs further investigation. It has
been shown that impaired insulin signaling can change the expression of drug
metabolizing enzymes which are responsible for glucuronidation and sulfation on
polyphenol metabolites such as UDP glucuronosyltransferase and sulfotransferases
(Kim and Novak 2007). The change of activities in phase II metabolizing enzymes is
very likely to alter the generation of conjugated polyphenol metabolites. It will be
interesting to further explore whether or not the function of UDP
glucuronosyltransferase, sulfotransferases and COMT are compromised in diabetic
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animals versus non diabetic ones. Since the lower plasma and brain levels of
polyphenols is the net balance between poor absorption and high excretion, further
investigation needs to address the intestinal absorption to establish the mechanism
of action.
Our data on the bioavailability of GSE/apple and bilberry extracts in young piglets
warrants further functionality study to determine whether these bioactives help
improve brain development regarding cognitive functions and learning abilities in young
children. It was demonstrated for the first time that there is differential brain deposition
of polyphneols and that flavonoids from studied fruit extracts preferably accumulate in
cerebellum. Since there is a growing consensus that cerebellum is involved in memory,
learning and cognition (Lalonde and Strazielle 2012; Wu and Hallett 2013), our data
support further investigation on the benefits of flavonoids on child brain development
and prevention or treatment of cerebellar disorders.
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